source
stringlengths 2
222
| date
stringlengths 19
19
| url
stringlengths 22
853
⌀ | text
stringlengths 0
10k
⌀ | title
stringlengths 0
701
| context_id
stringlengths 1
9
| document_id
stringclasses 2
values | document_type
stringclasses 2
values |
|---|---|---|---|---|---|---|---|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-04-27 06:30:00
| null |
TRANSACTION WITH CLS THERAPEUTICS FOR DNASE PLATFORM INCLUDES TWO PRE-CLINICAL DEVELOPMENT PROGRAMS AND CREATES NEAR-TERM CLINICAL DEVELOPMENT OPPORTUNITY DNASE BASED ONCOLOGY PLATFORM HAS THE POTENTIAL TO IMPROVE OUTCOMES OF EXISTING THERAPEUTIC AGENTS IN MULTIPLE SOLID TUMOR INDICATIONS XENETIC PLANS TO CONDUCT A PHASE 1 CLINICAL STUDY OF LEAD ASSET IN LOCALLY ADVANCED OR METASTATIC SOLID TUMORS COMPANY TO HOST UPDATE CONFERENCE CALL AND WEBCAST TODAY, APRIL 27TH AT 8:30 AM ET FRAMINGHAM, MA / ACCESSWIRE / APRIL 27, 2022 / XENETIC BIOSCIENCES, INC. (NASDAQ:XBIO) ("XENETIC" OR THE "COMPANY"), A BIOPHARMACEUTICAL COMPANY FOCUSED ON ADVANCING INNOVATIVE IMMUNE-ONCOLOGY TECHNOLOGIES FOR THE TREATMENT OF HARD TO TREAT CANCERS, TODAY ANNOUNCED THAT IT HAS ENTERED INTO EXCLUSIVE LICENSE AND SUBLICENSE AGREEMENTS WITH CLS THERAPEUTICS ("CLS") TO DEVELOP ITS INTERVENTIONAL DNASE BASED ONCOLOGY PLATFORM, WHICH IS AIMED AT IMPROVING OUTCOMES OF EXISTING TREATMENTS, INCLUDING IMMUNOTHERAPIES. XENETIC WILL HOST A CONFERENCE CALL AND WEBCAST, TODAY, APRIL 27, 2022, AT 8:30 A.M.
|
XENETIC BIOSCIENCES, INC. EXPANDS ONCOLOGY PIPELINE WITH IN-LICENSING OF DNASE BASED ONCOLOGY PLATFORM COMPRISING MULTIPLE THERAPEUTIC MODALITIES
|
XBIO
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-03-23 08:30:00
| null |
- XCARTTM CONTINUING TO ADVANCE TOWARD IND-ENABLING STUDIES - POLYXEN® PLATFORM TECHNOLOGY GROWING ROYALTY STREAM THROUGH LICENSE AGREEMENT - CLOSED THE YEAR WITH $18.2 MILLION OF CASH FRAMINGHAM, MA / ACCESSWIRE / MARCH 23, 2022 / XENETIC BIOSCIENCES, INC. (NASDAQ:XBIO) ("XENETIC" OR THE "COMPANY"), A BIOPHARMACEUTICAL COMPANY FOCUSED ON ADVANCING XCART™, A PERSONALIZED CAR T PLATFORM TECHNOLOGY ENGINEERED TO TARGET PATIENT- AND TUMOR-SPECIFIC NEOANTIGENS, TODAY REPORTED ITS FINANCIAL RESULTS FOR THE FULL YEAR 2021 AND PROVIDED A CORPORATE UPDATE. "OVER THE COURSE OF THE PAST YEAR, OUR TEAM HAS CONTINUED TO ADVANCE THE XCART PROGRAM THROUGH PRE-CLINICAL STUDIES, WHICH ARE KEY TO DEFINING THE BEST DEVELOPMENT PATHWAY FOR THIS NOVEL PLATFORM TECHNOLOGY.
|
XENETIC BIOSCIENCES, INC. REPORTS FULL YEAR 2021 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
|
XBIO
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-09-09 08:05:00
| null |
ALLOWANCE BOLSTERS INTELLECTUAL PROPERTY PORTFOLIO FOR DIFFERENTIATED PERSONALIZED CAR T PLATFORM TECHNOLOGY, XCART FRAMINGHAM, MA / ACCESSWIRE / SEPTEMBER 9, 2021 / XENETIC BIOSCIENCES, INC. (NASDAQ:XBIO) ("XENETIC" OR THE "COMPANY"), A BIOPHARMACEUTICAL COMPANY FOCUSED ON ADVANCING XCART™, A PERSONALIZED CAR T PLATFORM TECHNOLOGY ENGINEERED TO TARGET PATIENT- AND TUMOR-SPECIFIC NEOANTIGENS, TODAY ANNOUNCED THE UNITED STATES PATENT AND TRADEMARK OFFICE (USPTO) HAS ISSUED XENETIC A NOTICE OF ALLOWANCE FOR U.S. PATENT APPLICATION NUMBER 16/983,491 ENTITLED, "ARTICLES AND METHODS DIRECTED TO PERSONALIZED THERAPY OF CANCER," COVERING THE CO-ADMINISTRATION OF XCART-DERIVED CAR T CELLS TOGETHER WITH A PERSONALIZED VACCINE DESIGNED TO ENHANCE THE EFFECTIVENESS OF THE CAR T THERAPY. "WE BELIEVE OUR XCART PLATFORM TECHNOLOGY HAS THE POTENTIAL TO OFFER CANCER PATIENTS SUBSTANTIAL BENEFITS OVER THE EXISTING STANDARD OF CARE AND CURRENTLY APPROVED CAR T THERAPIES.
|
XENETIC BIOSCIENCES, INC. RECEIVES NOTICE OF ALLOWANCE FOR XCART(TM) PATENT
|
XBIO
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-08-13 08:05:00
| null |
CONTINUED EXECUTION ON XCART TM PRE-CLINICAL DEVELOPMENT PLAN AND PROGRESS TOWARD IND-ENABLING STUDIES STRONG ROYALTY GROWTH WITH POLYXEN® PLATFORM TECHNOLOGY BOLSTERED CASH POSITION WITH RECENTLY COMPLETED $12.5 MILLION PRIVATE PLACEMENT FRAMINGHAM, MA / ACCESSWIRE / AUGUST 13, 2021 / XENETIC BIOSCIENCES, INC. (NASDAQ:XBIO) ("XENETIC" OR THE "COMPANY"), A BIOPHARMACEUTICAL COMPANY FOCUSED ON ADVANCING XCART™, A PERSONALIZED CAR T PLATFORM TECHNOLOGY ENGINEERED TO TARGET PATIENT- AND TUMOR-SPECIFIC NEOANTIGENS, TODAY REPORTED ITS FINANCIAL RESULTS FOR THE SECOND QUARTER OF 2021 AND PROVIDED A CORPORATE UPDATE. "OVER THE COURSE OF THE SECOND QUARTER, WE CONTINUED TO EXECUTE OUR INNOVATIVE AND DIFFERENTIATED XCART PROGRAM, AND THE TECHNICAL PROGRESS WE'VE ACCOMPLISHED BRINGS US CLOSER TO THE CRITICAL MILESTONE OF CONDUCTING IND-ENABLING STUDIES IN THE UNITED STATES.
|
XENETIC BIOSCIENCES, INC. REPORTS SECOND QUARTER 2021 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
|
XBIO
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-07-28 14:00:00
| null |
FRAMINGHAM, MA / ACCESSWIRE / JULY 28, 2021 / XENETIC BIOSCIENCES, INC. (NASDAQ:XBIO) ("XENETIC" OR THE "COMPANY"), A BIOPHARMACEUTICAL COMPANY FOCUSED ON ADVANCING XCART™, A PERSONALIZED CAR T PLATFORM TECHNOLOGY ENGINEERED TO TARGET PATIENT- AND TUMOR-SPECIFIC NEOANTIGENS, TODAY ANNOUNCED THE CLOSING OF ITS PREVIOUSLY ANNOUNCED PRIVATE PLACEMENT WITH A SINGLE HEALTHCARE-FOCUSED INSTITUTIONAL INVESTOR FOR 4,629,630 SHARES OF ITS COMMON STOCK (OR COMMON STOCK EQUIVALENTS) AT A PURCHASE PRICE PER SHARE OF $2.70, PRICED AT-THE-MARKET UNDER NASDAQ RULES. THE GROSS PROCEEDS TO XENETIC TOTALED APPROXIMATELY $12.5 MILLION BEFORE DEDUCTING PLACEMENT AGENT FEES AND OTHER OFFERING EXPENSES.
|
XENETIC BIOSCIENCES, INC. ANNOUNCES CLOSING OF $12.5 MILLION PRIVATE PLACEMENT PRICED AT A PREMIUM TO MARKET
|
XBIO
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-05-12 07:00:00
| null |
CONTINUED EXECUTION ON XCART™ DEVELOPMENT PLAN WITH COMMENCEMENT OF EXPLORATORY PATIENT BIOPSY TRIAL EXPECTED TO POSITION THE COMPANY TO CONDUCT IND-ENABLING STUDIES IN THE UNITED STATES LICENSING PARTNERS LEVERAGING POLYXEN® PLATFORM TECHNOLOGY CONTINUE TO MAKE CLINICAL, REGULATORY AND COMMERCIAL ADVANCEMENT FRAMINGHAM, MA / ACCESSWIRE / MAY 12, 2021 / XENETIC BIOSCIENCES, INC. (NASDAQ:XBIO) ("XENETIC" OR THE "COMPANY"), A BIOPHARMACEUTICAL COMPANY FOCUSED ON ADVANCING XCART™, A PERSONALIZED CAR T PLATFORM TECHNOLOGY ENGINEERED TO TARGET PATIENT- AND TUMOR-SPECIFIC NEOANTIGENS, TODAY REPORTED ITS FINANCIAL RESULTS FOR THE FIRST QUARTER OF 2021 AND PROVIDED A CORPORATE UPDATE. "DURING THE FIRST QUARTER OUR FOCUS REMAINED ON ADVANCING THE DEVELOPMENT OF OUR XCART™ PLATFORM, WHICH WE BELIEVE HAS THE POTENTIAL TO PROVIDE A PERSONALIZED CAR T THERAPY TARGETING CANCERS WITH A PATIENT-AND TUMOR-SPECIFIC APPROACH.
|
XENETIC BIOSCIENCES, INC. REPORTS FIRST QUARTER 2021 FINANCIAL RESULTS
|
XBIO
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-03-29 08:05:00
| null |
- DATA FROM THE STUDY TO PROVIDE VALUABLE INSIGHTS AS THE COMPANY ADVANCES XCART LEAD PROGRAM IN NON-HODGKIN LYMPHOMA (NHL) TOWARDS INVESTIGATIONAL NEW DRUG (IND) FILING IN THE UNITED STATES - STUDY WILL EVALUATE THE XCART PROCESS OF NEOANTIGEN IDENTIFICATION AND GENERATION OF TUMOR-SPECIFIC CAR T CANDIDATES, IN A REAL-WORLD CLINICAL SETTING FRAMINGHAM, MA / ACCESSWIRE / MARCH 29, 2021 / XENETIC BIOSCIENCES, INC. (NASDAQ:XBIO) ("XENETIC" OR THE "COMPANY"), A BIOPHARMACEUTICAL COMPANY FOCUSED ON ADVANCING XCART, A PERSONALIZED CAR T PLATFORM TECHNOLOGY ENGINEERED TO TARGET PATIENT- AND TUMOR-SPECIFIC NEOANTIGENS, TODAY ANNOUNCED IT HAS RECEIVED APPROVAL TO COMMENCE ITS EXPLORATORY PATIENT BIOPSY STUDY IN EASTERN EUROPE EVALUATING XCART. "THE START OF THIS STUDY REPRESENTS AN IMPORTANT STEP FORWARD IN OUR PRECLINICAL DEVELOPMENT PROGRAM, AND WE LOOK FORWARD TO EVALUATING THE XCART PLATFORM APPLIED TO TUMOR SAMPLES FROM NHL PATIENTS CURRENTLY UNDER EVALUATION OR IN TREATMENT AT THE STUDY SITE.
|
XENETIC BIOSCIENCES, INC. RECEIVES APPROVAL TO COMMENCE EXPLORATORY STUDY OF XCART(TM)
|
XBIO
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-03-17 08:00:00
| null |
DRIVING DEVELOPMENT OF XCART™ PLATFORM AND LEVERAGING ACADEMIC COLLABORATIONS THROUGH PRECLINICAL DEVELOPMENT RECENT CLINICAL, REGULATORY AND COMMERCIAL ADVANCEMENTS FROM LICENSING PARTNERS LEVERAGING POLYXEN® PLATFORM TECHNOLOGY FRAMINGHAM, MA / ACCESSWIRE / MARCH 17, 2021 / XENETIC BIOSCIENCES, INC. (NASDAQ:XBIO) ("XENETIC" OR THE "COMPANY"), A BIOPHARMACEUTICAL COMPANY FOCUSED ON ADVANCING XCART™, A PERSONALIZED CAR T PLATFORM TECHNOLOGY ENGINEERED TO TARGET PATIENT- AND TUMOR-SPECIFIC NEOANTIGENS, TODAY REPORTED ITS FINANCIAL RESULTS FOR THE FOURTH QUARTER AND FULL YEAR 2020, AND PROVIDED A CORPORATE UPDATE. "NOTWITHSTANDING THE CHALLENGES PRESENTED BY THE COVID-19 PANDEMIC, 2020 WAS A YEAR OF SIGNIFICANT PROGRESS FOR THE COMPANY, INCLUDING THE ESTABLISHMENT OF PARTNERSHIPS AND ACADEMIC COLLABORATIONS AND ADVANCEMENT IN OUR DEVELOPMENT EFFORTS, IN PARTICULAR WITH RESPECT TO CAR DESIGN AND MODEL CELL LINE DEVELOPMENT, AS WELL AS THE STRENGTHENING OF OUR FINANCIAL POSITION.
|
XENETIC BIOSCIENCES, INC. REPORTS FOURTH QUARTER AND FULL YEAR 2020 FINANCIAL RESULTS
|
XBIO
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2020-06-24 10:30:00
| null |
XENETIC BIOSCIENCES- ON JUNE 22, CO GOT LETTER FROM NASDAQ THAT CO REGAINED COMPLIANCE.
|
XENETIC BIOSCIENCES SAYS ON JUNE 22 IT GOT LETTER FROM NASDAQ REGAINING COMPLIANCE
|
XBIO
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2020-05-14 20:30:00
| null |
XENETIC BIOSCIENCES INC - CASH ON HAND EXPECTED TO FUND OPERATIONS THROUGH MID-2021.XENETIC BIOSCIENCES INC - CONTINUING TO PROGRESS DISCUSSIONS TO SECURE ACADEMIC COLLABORATIONS TO ADVANCE XCART PLATFORM.XENETIC BIOSCIENCES INC QTRLY NET LOSS WAS ABOUT $1.2 MILLION VERSUS NET LOSS OF ABOUT $1.3 MILLION.
|
XENETIC BIOSCIENCES SAYS CASH ON HAND EXPECTED TO FUND OPERATIONS THROUGH MID-2021
|
XBIO
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2020-01-14 12:30:00
| null |
XENETIC BIOSCIENCES - ANNOUNCES PUBLICATION OF DATA FROM PARTNER TAKEDA'S PHASE 1/2 STUDY EVALUATING PROGRAM LEVERAGING POLYXEN(R) PLATFORM TECHNOLOGY.
|
XENETIC BIOSCIENCES - ANNOUNCES PUBLICATION OF DATA FROM PARTNER TAKEDA'S PHASE 1/2 STUDY
|
XBIO
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2019-11-15 13:30:00
| null |
XENETIC BIOSCIENCES INC QTRLY NET LOSS OF ABOUT $8.9 MILLION VERSUS ABOUT $1.8 MILLION.XENETIC BIOSCIENCES INC - COMPANY RAMPS UP ACTIVITIES TO EXECUTE XCART’S PRECLINICAL AND REGULATORY STRATEGY.XENETIC BIOSCIENCES INC - CASH RUNWAY EXPECTED TO FUND COMPANY THROUGH PRECLINICAL ADVANCEMENTS TOWARDS IND FILING.XENETIC BIOSCIENCES INC - ROYALTY STREAM RESULTING FROM THE TAKEDA SUBLICENSE EXPECTED TO COMMENCE BY THE END OF 2019.XENETIC BIOSCIENCES INC - ENDED Q3 2019 WITH ABOUT $12.0 MILLION IN CASH AND $11.2 MILLION OF WORKING CAPITAL.
|
XENETIC BIOSCIENCES QTRLY NET LOSS OF ABOUT $8.9 MLN VERSUS ABOUT $1.8 MLN
|
XBIO
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2019-11-13 22:30:00
| null |
XENETIC BIOSCIENCES, INC. ANNOUNCED EARNINGS RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2019. FOR THE THIRD QUARTER, THE COMPANY ANNOUNCED OPERATING LOSS WAS USD 8.946 MILLION COMPARED TO USD 1.814 MILLION A YEAR AGO. NET LOSS WAS USD 8.900 MILLION COMPARED TO USD 1.812 MILLION A YEAR AGO. BASIC LOSS PER SHARE FROM CONTINUING OPERATIONS WAS USD 2.67 COMPARED TO USD 2.31 A YEAR AGO. FOR THE NINE MONTHS, OPERATING LOSS WAS USD 11.651 MILLION COMPARED TO USD 5.636 MILLION A YEAR AGO. NET LOSS WAS USD 11.604 MILLION COMPARED TO USD 5.661 MILLION A YEAR AGO. BASIC LOSS PER SHARE FROM CONTINUING OPERATIONS WAS USD 9.07 COMPARED TO USD 7.58 A YEAR AGO.
|
XENETIC BIOSCIENCES, INC. REPORTS EARNINGS RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2019
|
XBIO
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2019-11-07 22:30:00
| null |
XENETIC BIOSCIENCES, INC., ANNUAL GENERAL MEETING, DEC 04, 2019, AT 10:00 US EASTERN STANDARD TIME. LOCATION: THE OFFICES OF HOLLAND & KNIGHT LLP, 701 BRICKELL AVENUE, SUITE 3300 MIAMI FLORIDA UNITED STATES AGENDA: TO ELECT THE BOARD NOMINEES TO THE BOARD OF DIRECTORS TO SERVE UNTIL THE NEXT ANNUAL MEETING AND THEIR SUCCESSORS ARE DULY ELECTED AND QUALIFIED; TO RATIFY THE SELECTION BY THE AUDIT COMMITTEE OF MARCUM LLP AS THE INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM OF THE COMPANY FOR ITS FISCAL YEAR ENDING DECEMBER 31, 2019; TO APPROVE THE NAMED EXECUTIVE OFFICER COMPENSATION; TO APPROVE THE COMPANY’S AMENDED AND RESTATED EQUITY INCENTIVE PLAN, TO, AMONG OTHER THINGS, INCREASE THE AGGREGATE NUMBER OF SHARES OF COMMON STOCK AUTHORIZED UNDER THE PLAN BY 750,000 SHARES; AND TO CONDUCT ANY OTHER BUSINESS PROPERLY BROUGHT BEFORE THE MEETING.
|
XENETIC BIOSCIENCES, INC., ANNUAL GENERAL MEETING, DEC 04, 2019
|
XBIO
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2019-10-28 22:30:00
| null |
XENETIC BIOSCIENCES, INC. PRESENTS AT 5TH ANNUAL DAWSON JAMES SMALL CAP GROWTH CONFERENCE, OCT-29-2019 11:45 AM. VENUE: WYNDHAM GRAND HOTEL, HARBOURSIDE PLACE, JUPITER, FLORIDA, UNITED STATES. SPEAKERS: JEFFREY F. EISENBERG, CEO & DIRECTOR.
|
XENETIC BIOSCIENCES, INC. PRESENTS AT 5TH ANNUAL DAWSON JAMES SMALL CAP GROWTH CONFERENCE, OCT-29-2019 11:45 AM
|
XBIO
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2019-10-23 18:30:00
| null |
OPKO HEALTH INC REPORTS A 4.7% STAKE IN XENETIC BIOSCIENCES INC AS OF SEPTEMBER 13, 2019 - SEC FILING.OPKO HEALTH INC PREVIOUSLY HAD A 7% STAKE IN XENETIC BIOSCIENCES INC AS OF JULY 19, 2019- SEC FILING.
|
OPKO HEALTH REPORTS 4.7% STAKE IN XENETIC BIOSCIENCES AS OF SEPT. 13
|
XBIO
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2019-10-10 22:30:00
| null |
XENETIC BIOSCIENCES, INC. PRESENTS AT BIO INVESTOR FORUM 2019, OCT-23-2019 02:45 PM. VENUE: THE WESTIN ST. FRANCIS, 335 POWELL STREET, SAN FRANCISCO, CALIFORNIA, UNITED STATES. SPEAKERS: JEFFREY F. EISENBERG, CEO & DIRECTOR.
|
XENETIC BIOSCIENCES, INC. PRESENTS AT BIO INVESTOR FORUM 2019, OCT-23-2019 02:45 PM
|
XBIO
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2019-09-29 22:30:00
| null |
ON SEPTEMBER 25, 2019, ROMAN KNYAZEV RESIGNED AS A MEMBER OF THE BOARD OF DIRECTORS OF XENETIC BIOSCIENCES, INC., EFFECTIVE IMMEDIATELY. THE RESIGNATION DID NOT RESULT FROM ANY DISAGREEMENT WITH THE COMPANY. ON SEPTEMBER 26, 2019, THE BOARD APPOINTED GRIGORY G. BORISENKO TO FILL SUCH VACANCY TO SERVE AS A DIRECTOR OF THE COMPANY, EFFECTIVE IMMEDIATELY. MR. BORISENKO WAS NOT APPOINTED TO SERVE ON ANY COMMITTEES OF THE BOARD UPON THE COMMENCEMENT OF HIS TERM AS A MEMBER OF THE BOARD. GRIGORY G. BORISENKO, PHD IS THE INVESTMENT DIRECTOR OF RUSNANO MANAGEMENT COMPANY LLC. MR. BORISENKO HAS OVER 20 YEARS OF SCIENTIFIC, MANAGEMENT AND STRATEGIC EXPERIENCE IN LIFE SCIENCE FIELD.
|
XENETIC BIOSCIENCES, INC. ANNOUNCES DIRECTORATE CHANGES
|
XBIO
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-05-22 09:00:00
| null |
XBIOTECH BELIEVES ITS DRUG CANDIDATE NATRUNIX COULD REVOLUTIONIZE ARTHRITIS TREATMENT XBIOTECH BELIEVES ITS DRUG CANDIDATE NATRUNIX COULD REVOLUTIONIZE ARTHRITIS TREATMENT
|
FDA AUTHORIZES PHASE II STUDY FOR NATRUNIX IN RHEUMATOID ARTHRITIS PATIENTS
|
XBIT
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-05-17 09:00:00
| null |
AUSTIN, TEXAS, MAY 17, 2023 (GLOBE NEWSWIRE) -- XBIOTECH INC. (NASDAQ: XBIT) (“XBIOTECH”) ANNOUNCED TODAY THAT IT COMMENCED A “MODIFIED DUTCH AUCTION” ISSUER TENDER OFFER TO PURCHASE UP TO $80,000,000 IN VALUE OF ITS COMMON SHARES, OR SUCH LESSER NUMBER OF COMMON SHARES AS ARE PROPERLY TENDERED AND NOT PROPERLY WITHDRAWN, AT A PRICE NOT GREATER THAN $4.00 NOR LESS THAN $3.80 PER COMMON SHARE, TO THE SELLER IN CASH, LESS ANY APPLICABLE WITHHOLDING TAXES AND WITHOUT INTEREST (THE “OFFER”). THE OFFER IS MADE UPON THE TERMS AND SUBJECT TO THE CONDITIONS DESCRIBED IN AN OFFER TO PURCHASE DATED MAY 17, 2023, THE RELATED LETTER OF TRANSMITTAL AND THE WEBSITE ESTABLISHED FOR PURPOSES OF EFFECTUATING THE OFFER. THE CLOSING PRICE OF XBIOTECH'S COMMON SHARES ON THE NASDAQ GLOBAL SELECT MARKET ON MAY 17, 2023, THE LAST TRADING DAY BEFORE THE COMMENCEMENT OF THE OFFER, WAS $3.48 PER SHARE. THE OFFER IS SCHEDULED TO EXPIRE AT 5:00 P.M., EASTERN TIME, ON JUNE 15, 2023, UNLESS THE OFFER IS EXTENDED.
|
XBIOTECH COMMENCES TENDER OFFER TO PURCHASE UP TO $80,000,000 WORTH OF ITS SHARES
|
XBIT
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-04-17 09:00:00
| null |
HUTRUKIN, A THERAPY DISCOVERED AND MANUFACTURED AT XBIOTECH, IS AIMED TO REDUCE BRAIN INJURY AFTER STROKE HUTRUKIN, A THERAPY DISCOVERED AND MANUFACTURED AT XBIOTECH, IS AIMED TO REDUCE BRAIN INJURY AFTER STROKE
|
XBIOTECH ANNOUNCES FIRST SUBJECT ENROLLMENT IN PHASE I CLINICAL TRIAL FOR HUTRUKIN, A NOVEL CANDIDATE THERAPY FOR STROKE
|
XBIT
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-10-13 12:46:00
| null |
INCA FUNDED PHASE I/II/III STUDY FOR NATRUNIX IN COMBINATION WITH TRIFLURIDINE/TIPIRACIL, THE TASKIN STUDY, LAUNCHES AT 20 LEADING MEDICAL CENTERS IN FRANCE INCA FUNDED PHASE I/II/III STUDY FOR NATRUNIX IN COMBINATION WITH TRIFLURIDINE/TIPIRACIL, THE TASKIN STUDY, LAUNCHES AT 20 LEADING MEDICAL CENTERS IN FRANCE
|
XBIOTECH ANNOUNCES FIRST PATIENT ENROLLED INTO THE FRENCH NATIONAL CANCER INSTITUTE (INCA) SPONSORED PHASE I/II/III CLINICAL STUDY FOR NATRUNIX™ THERAPY FOR COLORECTAL CANCER
|
XBIT
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-06-20 09:00:00
| null |
NOVEL NATRUNIX TREATMENT SHOWS PROMISE IN COMBINATION CHEMOTHERAPY FOR TREATMENT OF PANCREATIC CANCER NOVEL NATRUNIX TREATMENT SHOWS PROMISE IN COMBINATION CHEMOTHERAPY FOR TREATMENT OF PANCREATIC CANCER
|
XBIOTECH ANNOUNCES SUCCESSFUL COMPLETION OF PHASE I PORTION OF PANCREATIC CANCER STUDY
|
XBIT
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-04-28 09:00:00
| null |
ANSM APPROVES NATRUNIX FOR INSA FUNDED PHASE-I-III STUDY AT 20 LEADING MEDICAL CENTERS IN FRANCE ANSM APPROVES NATRUNIX FOR INSA FUNDED PHASE-I-III STUDY AT 20 LEADING MEDICAL CENTERS IN FRANCE
|
XBIOTECH ANNOUNCES FRENCH NATIONAL AGENCY (ANSM) APPROVAL AND NATIONAL CANCER INSTITUTE (INSA) FUNDING TO SUPPORT PHASE I/II/III CLINICAL STUDY FOR NATRUNIX™ IN COMBINATION WITH TRIFLURIDINE/TIPIRACIL (TASKIN) FOR TREATMENT OF METASTATIC COLORECTAL CANCER
|
XBIT
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-01-26 09:50:00
| null |
NATRUNIX-SQ, A TRUE HUMAN ANTIBODY THERAPY DISCOVERED AND MANUFACTURED AT XBIOTECH, IS AIMED AS A BREAKTHROUGH TREATMENT FOR ARTHRITIC DISEASE NATRUNIX-SQ, A TRUE HUMAN ANTIBODY THERAPY DISCOVERED AND MANUFACTURED AT XBIOTECH, IS AIMED AS A BREAKTHROUGH TREATMENT FOR ARTHRITIC DISEASE
|
XBIOTECH ANNOUNCES FIRST PATIENT ENROLLED IN PHASE I CLINICAL TRIAL FOR NOVEL ARTHRITIS THERAPY NATRUNIX-SQ
|
XBIT
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-12-13 08:00:00
| null |
LAUNCHING NOVEL TRUE HUMAN ANTIBODY THERAPY NATRUNIX™ TO TREAT RHEUMATOLOGY LAUNCHING NOVEL TRUE HUMAN ANTIBODY THERAPY NATRUNIX™ TO TREAT RHEUMATOLOGY
|
FDA APPROVES XBIOTECH'S IND IN RHEUMATOLOGY
|
XBIT
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-10-28 11:59:00
| null |
COMPANY COMMENCING PHASE I/II STUDY TO TEST SAFETY AND EFFICACY OF ITS NEW DRUG CANDIDATE TO REDUCE BRAIN INJURY AFTER STROKE COMPANY COMMENCING PHASE I/II STUDY TO TEST SAFETY AND EFFICACY OF ITS NEW DRUG CANDIDATE TO REDUCE BRAIN INJURY AFTER STROKE
|
XBIOTECH TO LAUNCH NOVEL CANDIDATE THERAPY FOR STROKE
|
XBIT
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-07-30 11:03:00
| null |
COMPANY DISTRIBUTED USD $75 MILLION TO SHAREHOLDERS COMPANY DISTRIBUTED USD $75 MILLION TO SHAREHOLDERS
|
XBIOTECH ANNOUNCES PAYMENT OF DIVIDEND TO HOLDERS OF COMMON STOCK
|
XBIT
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-07-06 16:30:00
| null |
AUSTIN, TEXAS, JULY 06, 2021 (GLOBE NEWSWIRE) -- XBIOTECH INC.'S (NASDAQ: XBIT) (“XBIOTECH”) BOARD OF DIRECTORS HAS DECLARED AN EXTRAORDINARY CASH DIVIDEND OF APPROXIMATELY $2.50 PER SHARE, OR UP TO AN AGGREGATE OF $75 MILLION, TO HOLDERS OF ITS COMMON STOCK. THIS ONE-TIME, SPECIAL DIVIDEND WILL BE PAYABLE ON JULY 23, 2021 TO STOCKHOLDERS OF RECORD AT THE CLOSE OF BUSINESS ON JULY 16, 2021.
|
XBIOTECH ANNOUNCES DIVIDEND TO HOLDERS OF COMMON STOCK
|
XBIT
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-06-30 11:46:00
| null |
COMPANY HAS NOW RECEIVED A TOTAL OF $750 MILLION FOR SALE OF ITS TRUE HUMAN ANTIBODY COMPANY HAS NOW RECEIVED A TOTAL OF $750 MILLION FOR SALE OF ITS TRUE HUMAN ANTIBODY
|
XBIOTECH ANNOUNCES RECEIPT OF $75 MILLION FROM SALE OF ANTIBODY
|
XBIT
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-06-23 08:30:00
| null |
XB2001 IS A NOVEL THERAPY THAT INTERRUPTS INFLAMMATION TO POTENTIALLY BLOCK GROWTH AND SPREAD OF TUMORS AND TO REDUCE TOXICITY OF CHEMOTHERAPY TREATMENT XB2001 IS A NOVEL THERAPY THAT INTERRUPTS INFLAMMATION TO POTENTIALLY BLOCK GROWTH AND SPREAD OF TUMORS AND TO REDUCE TOXICITY OF CHEMOTHERAPY TREATMENT
|
XBIOTECH ANNOUNCES FIRST PATIENT ENROLLED IN CLINICAL TRIAL EVALUATING XB2001 FOR THE TREATMENT OF PANCREATIC CANCER
|
XBIT
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-04-19 04:00:00
| null |
XBIOTECH'S NEW DRUG TO ENTER CLINICAL STUDIES IN COMBINATION THERAPY FOR PANCREATIC CANCER XBIOTECH'S NEW DRUG TO ENTER CLINICAL STUDIES IN COMBINATION THERAPY FOR PANCREATIC CANCER
|
FDA GIVES GO-AHEAD FOR XBIOTECH'S CANDIDATE THERAPY FOR PHASE I/II DOUBLE-BLIND PLACEBO CONTROLLED STUDY IN PANCREATIC CANCER
|
XBIT
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-01-21 08:15:00
| null |
WITH NEW INFECTIOUS STRAIN RAPIDLY SPREADING, XBIOTECH ESTABLISHES DATA INDICATING ITS CANDIDATE TRUE HUMAN™ COVID-19 THERAPY MAY BE EFFECTIVE FOR TREATING NEW MUTANT STRAIN WITH NEW INFECTIOUS STRAIN RAPIDLY SPREADING, XBIOTECH ESTABLISHES DATA INDICATING ITS CANDIDATE TRUE HUMAN™ COVID-19 THERAPY MAY BE EFFECTIVE FOR TREATING NEW MUTANT STRAIN
|
XBIOTECH CANDIDATE TRUE HUMAN™ COVID-19 THERAPY FOUND TO TARGET HIGHLY INFECTIOUS EMERGING STRAIN
|
XBIT
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-01-19 08:15:00
| null |
APPOINTMENTS INCLUDE: CHAIR, CLAY JOHNSTON, M.D., PH.D. AS WELL AS MEMBERS GREG ALBERS, M.D. AND BRETT CUCCHIARA, M.D. APPOINTMENTS INCLUDE: CHAIR, CLAY JOHNSTON, M.D., PH.D. AS WELL AS MEMBERS GREG ALBERS, M.D. AND BRETT CUCCHIARA, M.D.
|
XBIOTECH ANNOUNCES CEREBROVASCULAR MEDICAL ADVISORY BOARD & DEVELOPMENT OF NEW STROKE THERAPY
|
XBIT
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2020-11-19 08:15:00
| null |
CANDIDATE THERAPY FOR FLU+COVID-19 CO-INFECTION SHOWS POTENT ANTI-VIRAL POTENTIAL CANDIDATE THERAPY FOR FLU+COVID-19 CO-INFECTION SHOWS POTENT ANTI-VIRAL POTENTIAL
|
XBIOTECH DATA SHOWS EFFECTIVE ANTI-VIRUS ACTIVITY FOR TRUE HUMAN ANTIBODIES IN ITS CANDIDATE INFLUENZA-COVID-19 THERAPEUTIC COCKTAIL
|
XBIT
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2020-09-21 10:30:00
| null |
XBIOTECH DEVELOPING TRUE HUMAN ANTIBODY COMBINATION AS CANDIDATE TREATMENT FOR INFLUENZA-COVID-19 CO-INFECTIONS.XBIOTECH INC - DEVELOPING NEW CANDIDATE THERAPY CALLED FLUVID FOR TREATING ILLNESS CAUSED BY COMBINED INFECTIONS WITH INFLUENZA AND COVID-19.XBIOTECH INC - FLUVID WILL CONTAIN IH201 AND IH302 ANTIBODIES ALONG WITH COMPANY'S ANTI-COVID-19 ANTIBODY.
|
XBIOTECH SAYS CO DEVELOPING TRUE HUMAN ANTIBODY COMBINATION FOR INFLUENZA-COVID-19 CO-INFECTIONS
|
XBIT
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2019-12-07 06:30:00
| null |
PRESS RELEASE - XBIOTECH ANNOUNCES AGREEMENT TO SELL TRUE HUMAN ANTIBODY BERMEKIMAB TARGETING IL-1A TO JANSSEN.XBIOTECH MAY RECEIVE UP TO $600 MILLION IN POTENTIAL MILESTONE PAYMENTS.XBIOTECH -CO EXPECTS TO GENERATE ADDITIONAL REVENUE FROM MANUFACTURING SUPPLY AGREEMENT, CLINICAL SERVICES AGREEMENT WITH JANSSEN OVER NEXT 2 YEARS.
|
XBIOTECH ANNOUNCES AGREEMENT TO SELL TRUE HUMAN ANTIBODY BERMEKIMAB TARGETING IL-1A TO JANSSEN
|
XBIT
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2019-12-07 05:30:00
| null |
JANSSEN TO ACQUIRE INVESTIGATIONAL BERMEKIMAB FROM XBIOTECH.JANSSEN BIOTECH- UNDER TERMS OF AGREEMENT, JANSSEN WILL ASSUME RESPONSIBILITY FOR CLINICAL PROGRAM, WORKING CLOSELY WITH XBIOTECH.JANSSEN BIOTECH - WILL PAY XBIOTECH A PURCHASE PRICE OF $750 MILLION FOR RIGHTS TO BERMEKIMAB.
|
JANSSEN TO ACQUIRE INVESTIGATIONAL BERMEKIMAB FROM XBIOTECH
|
XBIT
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2019-11-18 22:30:00
| null |
XBIOTECH INC. ANNOUNCED RAPID ENROLLMENT IN ITS RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 CLINICAL STUDY EVALUATING BERMEKIMAB IN PATIENTS WITH MODERATE TO SEVERE HIDRADENITIS SUPPURATIVA (HS). THE STUDY IS CHAIRED BY RENOWNED INVESTIGATIVE DERMATOLOGIST ALICE GOTTLIEB, MD, PHD (MEDICAL DIRECTOR OF DERMATOLOGY AT THE MOUNT SINAI BETH ISRAEL CAMPUS AND CLINICAL PROFESSOR AT THE ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI) AND WILL ENROLL APPROXIMATELY 150 PATIENTS. XBIOTECH ANNOUNCED THE FIRST PATIENT ENROLLED IN THE STUDY ON OCTOBER 23, 2019. XBIOTECH IS ALREADY UPDATING STATUS OF THE STUDY, REPORTING THAT 51 PATIENTS HAVE NOW BEEN RANDOMIZED, OR ASSIGNED TO AN INVESTIGATIONAL ARM OF THE STUDY. BERMEKIMAB HAS BEEN TESTED IN TWO PREVIOUS CLINICAL STUDIES. IN A RECENT OPEN LABEL STUDY (N=42), 61% OF PATIENTS WITH NO PRIOR BIOLOGICAL THERAPY AND 63% OF PATIENTS WHO HAD FAILED PREVIOUS BIOLOGICAL THERAPY (I.E. ADALIMUMAB) ACHIEVED A POSITIVE HISCR AT 12 WEEKS. ADDITIONALLY, THE MAJORITY OF PATIENTS IN BOTH GROUPS ACHIEVED CLINICALLY SIGNIFICANT REDUCTION IN PAIN FROM THEIR DISEASE. THESE RESULTS WERE PRESENTED AT THE AMERICAN ACADEMY OF DERMATOLOGY (AAD) IN 2019. IN AN EARLIER DOUBLE-BLIND, PLACEBO CONTROLLED, RANDOMIZED STUDY WHICH ALSO EVALUATED BERMEKIMAB IN THE TREATMENT OF HS, THE STUDY’S PRIMARY ENDPOINT WAS MET, DEMONSTRATING SIGNIFICANT IMPROVEMENT OF HISCR IN PATIENTS TREATED WITH BERMEKIMAB COMPARED TO CONTROL AFTER 12 WEEKS OF THERAPY (RESPONSE RATE OF 60% VS 10%, RESPECTIVELY (P=0.035)). THE PRIMARY ENDPOINT FOR THE CURRENT STUDY IS THE PERCENTAGE OF SUBJECTS ACHIEVING A HIDRADENITIS SUPPURATIVA CLINICAL RESPONSE (HISCR) AT WEEK 12. MULTIPLE SECONDARY EFFICACY ENDPOINTS WILL BE ASSESSED AFTER 12 AND 16 WEEKS OF THERAPY, INCLUDING: NUMERICAL RATING SCALE (NRS) FOR PAIN AND ITCH; MODIFIED SARTORIUS SCORE; DERMATOLOGY LIFE QUALITY INDEX (DLQI); HOSPITAL ANXIETY AND DEPRESSION SCALE (HADS); AND PATIENT GLOBAL IMPRESSION OF CHANGE AND SEVERITY (PGI-C, PGI-S).
|
XBIOTECH INC. ANNOUNCES RAPID ENROLLMENT FOR ITS RANDOMIZED MULTI-CENTER CLINICAL STUDY FOR BERMEKIMAB IN PATIENTS WITH HIDRADENITIS SUPPURATIVA
|
XBIT
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2019-11-11 22:30:00
| null |
XBIOTECH INC. HAS ENROLLED THE FIRST PATIENT IN A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 CLINICAL STUDY TO EVALUATE ITS IL-1A BLOCKING ANTIBODY THERAPY IN PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS (AD) (ALSO KNOWN AS ECZEMA). THE STUDY WILL ASSESS WEEKLY BERMEKIMAB THERAPY TO REDUCE INFLAMMATORY SKIN LESIONS, ITCH, AND PAIN IN PATIENTS SUFFERING FROM ECZEMA. THE STUDY WILL COMPARE THREE GROUPS OF PATIENTS OVER 16 WEEKS OF TREATMENT: A WEEKLY DOSING GROUP, A BIWEEKLY DOSING GROUP, AND A PLACEBO GROUP. PERCENTAGE OF PATIENTS WHO ACHIEVE A 75% REDUCTION IN SKIN DISEASE AFTER 16 WEEKS OF TREATMENT WILL BE THE PRIMARY MEASURE OF RESPONSE. THE ECZEMA AREA SEVERITY INDEX (EASI) SCORING SYSTEM WILL BE USED TO ASSESS SEVERITY OF INFLAMMATORY SKIN LESIONS. ANOTHER CRUCIAL ASSESSMENT WILL BE PATIENT ITCH, WHICH IS OFTEN SEVERE AND UNRELENTING IN THIS DISEASE. A NUMERIC RATING SCALE (NRS) WILL BE USED TO ASSESS ITCH AND PAIN AT VARIOUS TIMEPOINTS RANGING FROM 4-16 WEEKS. BERMEKIMAB WAS PREVIOUSLY TESTED IN A CLINICAL STUDY OF PATIENTS WITH MODERATE TO SEVERE AD. THOSE RESULTS WERE PREVIOUSLY PRESENTED AT THE ANNUAL CONFERENCES OF THE AMERICAN ACADEMY OF DERMATOLOGY (AAD) AND THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEROLOGY (EADV) BY RENOWNED DERMATOLOGISTS DR. ERIC SIMPSON AND DR. ALICE GOTTLIEB, RESPECTIVELY. THE FINDINGS SHOWED THAT AFTER ONLY 8 WEEKS OF BERMEKIMAB THERAPY, 75% OF PATIENTS HAD ACHIEVED 75% IMPROVEMENT IN DISEASE SEVERITY AS ASSESSED BY EASI SCORE (THE CURRENT STANDARD OF CARE FOR BIOLOGICAL THERAPY INVOLVES A 16 WEEK TREATMENT REGIMEN AND IS ASSOCIATED WITH 44-51% OF PATIENTS ACHIEVING 75% IMPROVEMENT). BERMEKIMAB THERAPY WAS ALSO ASSOCIATED WITH A DRAMATIC REDUCTION IN ITCH AND PAIN, WITH THREE FOURTHS OF PATIENTS ACHIEVING CLINICALLY SIGNIFICANT REDUCTION IN ITCH, AND 86% ACHIEVING CLINICALLY SIGNIFICANT REDUCTION IN PAIN AFTER ONLY 8 WEEKS OF TREATMENT. INFLAMMATION PLAYS A MAJOR ROLE IN THE INDUCTION AND PROGRESSION OF SEVERAL SKIN DISEASES, INCLUDING ECZEMA OR ATOPIC DERMATITIS. BERMEKIMAB BLOCKS THE ACTION OF THE POTENT INFLAMMATORY SUBSTANCE IL-1? FOUND IN SKIN. IT HAS BEEN DEMONSTRATED THAT IL-1? IS NECESSARY FOR INDUCING CHRONIC SKIN INFLAMMATION THROUGH ABERRANT STORES OF INTRACELLULAR IL-1? IN KERATINOCYTES, WHICH CONSTITUTE APPROXIMATELY 90% OF SKIN CELLS. IL-1? SECRETION HAS SHOWN NOT ONLY TO BE NECESSARY COMPONENT IN DRIVING SKIN INFLAMMATION, BUT BY ITSELF SUFFICIENT TO DO SO. THEREFORE, NEUTRALIZING IL-1? ACTIVITY THROUGH AN INHIBITOR SUCH AS BERMEKIMAB HAS PROMISE TO RESOLVE CHRONIC SKIN INFLAMMATION AND LOOKS TO BE A KEY TARGET FOR TREATING ATOPIC DERMATITIS, ALONG WITH OTHER INFLAMMATORY SKIN DISEASES.
|
XBIOTECH INC. ANNOUNCES FIRST PATIENT ENROLLED IN PLACEBO-CONTROLLED CLINICAL STUDY EVALUATING ITS ANTI-IL-1? THERAPY BERMEKIMAB IN PATIENTS WITH ATOPIC DERMATITIS (ECZEMA)
|
XBIT
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2019-10-22 22:30:00
| null |
XBIOTECH INC. ANNOUNCED THAT THE FIRST PATIENT WAS ENROLLED IN ITS RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 CLINICAL STUDY EVALUATING BERMEKIMAB IN PATIENTS WITH MODERATE TO SEVERE HIDRADENITIS SUPPURATIVA (HS). THE MULTI-CENTER, INTERNATIONAL STUDY WILL ENROLL APPROXIMATELY 150 PATIENTS INTO THREE ARMS: TWO BERMEKIMAB DOSING REGIMENS VERSUS A PLACEBO ARM OVER SIXTEEN (16) WEEKS OF THERAPY. THE STUDY IS CHAIRED BY RENOWNED INVESTIGATIVE DERMATOLOGIST ALICE GOTTLIEB, MD, PHD, MEDICAL DIRECTOR OF DERMATOLOGY AT THE MOUNT SINAI BETH ISRAEL CAMPUS AND CLINICAL PROFESSOR AT THE ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI. THE STUDY'S PRIMARY ENDPOINT IS THE PERCENTAGE OF SUBJECTS ACHIEVING HIDRADENITIS SUPPURATIVA CLINICAL RESPONSE (HISCR) AT WEEK 12. MULTIPLE SECONDARY EFFICACY ENDPOINTS WILL BE ASSESSED AFTER 12 AND 16 WEEKS OF THERAPY, INCLUDING: NUMERICAL RATING SCALE (NRS) FOR PAIN AND ITCH; MODIFIED SARTORIUS SCORE; DERMATOLOGY LIFE QUALITY INDEX (DLQI); HOSPITAL ANXIETY AND DEPRESSION SCALE (HADS); AND PATIENT GLOBAL IMPRESSION OF CHANGE AND SEVERITY (PGI-C, PGI-S). BERMEKIMAB HAS DEMONSTRATED ITS SAFETY AND EFFICACY TREATING HS IN TWO PREVIOUS CLINICAL STUDIES. A RECENT OPEN LABEL STUDY DEMONSTRATED THAT WEEKLY BERMEKIMAB IS AN EFFECTIVE THERAPY, AS MEASURED BY IMPROVEMENT IN DISEASE ACCORDING TO HISCR, THE KEY MEASURE OF DISEASE IN HS. IN THE STUDY, 61% OF PATIENTS WITH NO PRIOR BIOLOGICAL THERAPY ACHIEVED POSITIVE HISCR AT 12 WEEKS, AND 63% OF PATIENTS WHO HAD FAILED PREVIOUS BIOLOGICAL THERAPY (I.E. ADALIMUMAB) ACHIEVED A POSITIVE HISCR AT 12 WEEKS. ANOTHER UNRIVALED FINDING IN THE STUDY WAS A SIGNIFICANT TREATMENT-RELATED REDUCTION OF PAIN IN HS PATIENTS. REDUCING PAIN IS WIDELY RECOGNIZED AMONG EXPERTS AS A KEY OBJECTIVE FOR HS TREATMENT, BUT THIS SYMPTOM HAS BEEN LARGELY UNADDRESSED BY AVAILABLE DRUGS. PAIN WAS ASSESSED WITH A PATIENT QUESTIONNAIRE USING A NUMERICAL RATING SCALE FROM 0 TO 10. A 30% AND =1-UNIT REDUCTION IN PAIN SCORE IS CONSIDERED A CLINICALLY IMPORTANT RELIEF FROM PAIN, AND NO APPROVED MONOTHERAPY FOR HS HAS ELICITED A CLINICALLY SIGNIFICANT EFFECT ON PAIN. REMARKABLY, A SUBSTANTIAL MAJORITY OF PATIENTS TREATED WITH WEEKLY BERMEKIMAB ACHIEVED THIS ENDPOINT: 67% AND 72% AT WEEK 12 WHO HAD PRIOR OR NO PRIOR ANTI-TNF THERAPY, RESPECTIVELY.
|
XBIOTECH ANNOUNCES FIRST PATIENT ENROLLED IN RANDOMIZED MULTI-CENTER CLINICAL STUDY EVALUATING BERMEKIMAB THERAPY IN PATIENTS WITH HIDRADENITIS SUPPURATIVA
|
XBIT
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2019-10-01 22:30:00
| null |
XBIOTECH ANNOUNCED THE FIRST PATIENT WAS ENROLLED IN A CLINICAL STUDY EVALUATING BERMEKIMAB THERAPY IN ADULTS WITH SYSTEMIC SCLEROSIS (SSC), OTHERWISE KNOWN AS SCLERODERMA, A DEVASTATING INFLAMMATORY SYNDROME CHARACTERIZED BY CHRONIC INFLAMMATION IN THE BLOOD VESSELS, SKIN, AND OTHER ORGANS. THE RANDOMIZED DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL WILL EVALUATE EFFICACY OF WEEKLY BERMEKIMAB MONOTHERAPY VERSUS PLACEBO. THE PRIMARY ENDPOINT OF THE STUDY WILL BE MEASURED AT 12 WEEKS, AND WILL ASSESS SSC DISEASE SEVERITY USING A COMBINATION OF RHEUMATOLOGICAL, CLINICAL, AND PHYSIOLOGICAL MEASURES. THE STUDY WILL RANDOMIZE PATIENTS 1:1 TO RECEIVE EITHER WEEKLY SUBCUTANEOUS INJECTIONS OF BERMEKIMAB OR PLACEBO. THE STUDY WILL ALSO INCLUDE AN OPEN LABEL WEEKLY BERMEKIMAB TREATMENT REGIMEN DURING WEEKS 13-24, WHERE PATIENTS WILL CONTINUE TO BE EVALUATED USING THE SAME ENDPOINTS. SSC IS CHARACTERIZED BY SYSTEMIC INFLAMMATION THAT RESULTS IN INJURY TO BLOOD VESSELS, AND FIBROSIS OF THE SKIN AND INTERNAL ORGANS1. SKIN LESIONS CAN BE SEVERE, RESULTING IN DISFIGURATION AND DEBILITATING PAIN. IN ADDITION, PATIENTS SUFFERING FROM SSC HAVE SUBSTANTIALLY REDUCED LIFE EXPECTANCY DUE TO THE FIBROSIS THAT OCCURS IN VITAL ORGANS AND CHRONIC INFLAMMATION OF THE BLOOD VESSELS. WHILE THE CAUSE OF SSC IS UNKNOWN, PATHOGENESIS OF THE DISEASE IS UNDERSTOOD TO INVOLVE ERRANT ACTIVATION OF FIBROBLASTS. IN NORMAL ORGANS AND TISSUES, FIBROBLAST CELLS PLAY A CRUCIAL ROLE IN BUILDING THE STRUCTURAL FRAMEWORK OF CONNECTIVE TISSUE THAT HOLDS THE ORGANS AND TISSUES TOGETHER. FIBROBLASTS PRODUCE THE EXTRACELLULAR MATRIX SUBSTANCES THAT ACTUALLY ENABLE THE ORGAN STRUCTURE. WHEN FIBROBLASTS ARE ERRANTLY ACTIVATED IN SSC, THEY BECOME HYPERACTIVE AND PRODUCE EXCESSIVE EXTRACELLULAR MATRIX, WHICH IS THE BASIS FOR FIBROSIS. AN INITIAL STEP IN THE SSC DISEASE PROCESS IS BELIEVED TO BE THE RELEASE OF THE POTENT INFLAMMATORY CYTOKINE INTERLEUKIN-1 ALPHA (IL-1?) FROM KERATINOCYTES IN THE EPIDERMIS3. THE RELEASE OF IL-1? RESULTS IN THE PRODUCTION OF A MYRIAD OF OTHER INFLAMMATORY CYTOKINES, INCLUDING IL-6, TNF, IL-8, IL-10, AND OTHERS FROM SURROUNDING TISSUES. BLOCKING IL-1? COULD ABROGATE THE PATHOLOGICAL CASCADE THAT OCCURS IN THIS DISEASE. BERMEKIMAB SPECIFICALLY BINDS AND NEUTRALIZES IL-1?. ERRANT IL-1? PRODUCTION HAS BEEN REPEATEDLY SHOWN TO OCCUR IN CELLS OF PATIENTS WITH SSC (8,9). IL-1? LEVELS ARE ELEVATED IN SSC PATIENTS10,11, INCLUDING IN THE SKIN AND IN LUNG FLUIDS OF SSC PATIENTS WITH PULMONARY FIBROSIS; AND WHEN IL-1? PRODUCTION IS INDUCED IN NORMAL FIBROBLASTS, THESE TAKE ON THE CHARACTERISTICS OF SSC FIBROBLASTS. THE MOST COMMON AFFECTED ORGANS IN SSC ARE THE SKIN, THE GASTROINTESTINAL TRACT, THE LUNGS, AND THE HEART. CAPILLARY ENDOTHELIUM IS INVOLVED, LEADING TO ISCHEMIA AND DIGITAL NECROSIS. PATIENTS DEVELOP AN INTERSTITIAL LUNG DISEASE (ILD) PROTOTYPE DOMINATED BY PULMONARY HYPERTENSION (PHA) AND FAILED GAS EXCHANGE. ALMOST ALL PATIENTS ALSO HAVE SIGNS OF INTESTINAL DYSMOTILITY LEADING TO GASTROINTESTINAL REFLUX AND BLOATING. HALLMARKS OF SSC ARE FIBROSIS OF THE SKIN AND INTERNAL ORGANS AND VASCULOPATHY. SSC IS THE ONLY RHEUMATIC DISORDER ACCOMPANIED BY SUBSTANTIAL LETHALITY; SO FAR NO SPECIFIC TREATMENT TARGETING THE MECHANISM OF PATHOGENESIS IS AVAILABLE.
|
XBIOTECH ANNOUNCES FIRST PATIENT IN CLINICAL STUDY TO EVALUATE BERMEKIMAB IN SYSTEMIC SCLEROSIS
|
XBIT
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2019-09-26 22:30:00
| null |
XBIOTECH ANNOUNCED THAT DR. ALICE GOTTLIEB WILL BE PRESENTING CLINICAL FINDINGS FOR BERMEKIMAB IN THE TREATMENT OF ATOPIC DERMATITIS (AD) AT THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (EADV) CONGRESS BEING HELD IN MADRID SPAINOCTOBER 9-13TH. DR. GOTTLIEB WILL PRESENT DATA FROM A MULTICENTER, PHASE 2 STUDY IN WHICH BERMEKIMAB MONOTHERAPY SHOWED RAPID AND DOSE DEPENDENT IMPROVEMENT IN AD. A HIGHLIGHT OF THE DATA TO BE REPORTED IS THE OBSERVATION THAT AFTER ONLY 8 WEEKS OF BERMEKIMAB THERAPY, THREE-FOURTHS OF PATIENTS ACHIEVED 75% IMPROVEMENT IN THEIR ECZEMA AREA AND SEVERITY INDEX (EASI 75) SCORES, A KEY MEASURE OF DISEASE SEVERITY IN AD. THE CURRENT STANDARD OF CARE AND THE ONLY APPROVED BIOLOGICAL THERAPY FOR AD INVOLVES A 16 WEEK TREATMENT REGIMEN, WHICH CLINICAL TRIALS HAVE SHOWN TO RESULT IN 44-51% OF PATIENTS ACHIEVING 75% IMPROVEMENT IN EASI SCORE. ANOTHER KEY FINDING TO BE REPORTED IN THE BERMEKIMAB STUDY WAS A DRAMATIC REDUCTION IN ITCH, WHICH CAN BE DEBILITATING IN ECZEMA PATIENTS.
|
XBIOTECH ANNOUNCES ORAL PRESENTATION OF ATOPIC DERMATITIS RESULTS FOR BERMEKIMAB AT 2019 EADV CONGRESS IN MADRID, SPAIN
|
XBIT
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2020-09-10 08:30:00
| null |
EXACTEARTH ANNOUNCES Q3 FISCAL 2020 FINANCIAL RESULTS.EXACTEARTH LTD - QTRLY REVENUE WAS $4.8 MILLION, UP 19%.EXACTEARTH LTD - QTRLY LOSS PER SHARE $0.04.
|
EXACTEARTH ANNOUNCES Q3 FISCAL 2020 FINANCIAL RESULTS
|
XCT.TO
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2020-07-06 09:30:00
| null |
EXACTEARTH ANNOUNCES $7.0 MILLION EXPANSION OF CHANNEL PARTNER AGREEMENT.EXACTEARTH LTD - AMENDED AGREEMENT EXTENDS CURRENT AGREEMENT BETWEEN COMPANIES BY THREE-AND-A-HALF YEARS THROUGH TO DECEMBER 2023.EXACTEARTH-ESTIMATES THAT AMENDED AGREEMENT WILL GENERATE ADDITIONAL INCREMENTAL REVENUES OF ABOUT $7.0 MILLION, OR $2.0 MILLION PER YEAR ON ANNUALIZED BASIS.
|
EXACTEARTH ANNOUNCES $7.0 MLN EXPANSION OF CHANNEL PARTNER AGREEMENT
|
XCT.TO
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2020-06-11 08:30:00
| null |
EXACTEARTH ANNOUNCES Q2 FISCAL 2020 FINANCIAL RESULTS.EXACTEARTH LTD - QTRLY REVENUE WAS $4.4 MILLION, UP 13% COMPARED TO $3.9 MILLION IN Q2 FISCAL 2019.EXACTEARTH LTD - ORDER BOOKINGS BACKLOG AT END OF Q2 2020 WAS $24.9 MILLION COMPARED TO $24.6 MILLION AT END OF Q2 2019.EXACTEARTH LTD - NEW ORDER BOOKINGS WERE $3.5 MILLION IN QUARTER, DOWN 41% COMPARED TO $6.0 MILLION IN Q2 FISCAL 2019.EXACTEARTH LTD - QTRLY LOSS PER SHARE $0.13.
|
EXACTEARTH REPORTS Q2 LOSS PER SHARE OF $0.13
|
XCT.TO
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2020-03-12 08:30:00
| null |
EXACTEARTH ANNOUNCES Q1 FISCAL 2020 FINANCIAL RESULTS.EXACTEARTH LTD QTRLY REVENUE WAS $4.1 MILLION, UP 17% COMPARED TO $3.5 MILLION IN Q1 FISCAL 2019.EXACTEARTH LTD QTRLY ORDER BOOKINGS WERE $7.1 MILLION COMPARED TO $3.0 MILLION IN Q1 FISCAL 2019.EXACTEARTH LTD QTRLY LOSS PER SHARE OF $0.03.EXACTEARTH LTD QTRLY SUBSCRIPTION SERVICES REVENUE WAS $3.8 MILLION, UP 23% COMPARED TO $3.1 MILLION IN Q1 FISCAL 2019.
|
EXACTEARTH POSTS Q1 LOSS PER SHARE OF $0.03
|
XCT.TO
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2020-01-29 10:30:00
| null |
EXACTEARTH ANNOUNCES Q4 AND YEAR-END FISCAL 2019 FINANCIAL RESULTS.EXACTEARTH LTD QTRLY LOSS PER SHARE $0.10.EXACTEARTH LTD QTRLY REVENUE $3.8 MILLION VERSUS $3.8 MILLION.
|
EXACTEARTH REPORTS Q4 LOSS PER SHARE $0.10
|
XCT.TO
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2020-01-21 09:30:00
| null |
EXACTEARTH ANNOUNCES UPDATED TERMS TO SATELLITE AIS BUSINESS AGREEMENT WITH L3HARRIS TECHNOLOGIES.EXACTEARTH - REACHED AGREEMENT ON UPDATED TERMS TO ORIGINAL SATELLITE-AIS BUSINESS AGREEMENT WITH L3HARRIS TECHNOLOGIES ENTERED IN 2015.EXACTEARTH - UNDER AMENDED & RESTATED AGREEMENT, CO WILL PAY 30% SHARE OF SAIS DATA REVENUE FOR PORTION OF CO'S ANNUAL SAIS DATA REVENUE IN EXCESS OF $16 MILLION.EXACTEARTH - WILL RECEIVE NO SHARE OF L3HARRIS SAIS DATA REVENUES.
|
EXACTEARTH REACHES AGREEMENT ON UPDATED TERMS TO SATELLITE AIS BUSINESS AGREEMENT WITH L3HARRIS TECHNOLOGIES
|
XCT.TO
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-07-14 16:01:00
| null |
CHICAGO--(BUSINESS WIRE)--EXICURE, INC. REPORTS FIRST QUARTER 2023 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.
|
EXICURE, INC. REPORTS FIRST QUARTER 2023 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
|
XCUR
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-05-26 16:01:00
| null |
CHICAGO--(BUSINESS WIRE)--EXICURE, INC. (NASDAQ: XCUR) (“EXICURE” OR THE “COMPANY”), HISTORICALLY AN EARLY-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON DEVELOPING NUCLEIC ACID THERAPIES TARGETING RIBONUCLEIC ACID AGAINST VALIDATED TARGETS, PREVIOUSLY ANNOUNCED AN ONGOING STRATEGY TO EXPLORE STRATEGIC ALTERNATIVES TO MAXIMIZE STOCKHOLDER VALUE, AND AS PART OF SUCH ONGOING EFFORT, PREVIOUSLY ANNOUNCED THE APPOINTMENT OF JUNG SANG (MICHAEL) KIM AS CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER OF T.
|
EXICURE, INC. ANNOUNCES SUPPORT OF CEO IN ITS ONGOING EXPLORATION OF STRATEGIC ALTERNATIVES
|
XCUR
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-05-19 16:01:00
| null |
CHICAGO--(BUSINESS WIRE)--EXICURE, INC. (“EXICURE” OR THE “COMPANY”) (NASDAQ: XCUR), ANNOUNCED TODAY IT RECEIVED A NOTICE OF NON-COMPLIANCE FROM NASDAQ STOCK MARKET LLC (“NASDAQ”) ON MAY 17, 2023 NOTIFYING THE COMPANY THAT, AS A RESULT OF THE COMPANY'S FAILURE TO TIMELY FILE ITS QUARTERLY REPORT ON FORM 10-Q FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2023 (THE “FORM 10-Q”), THE COMPANY IS NOT IN COMPLIANCE WITH NASDAQ LISTING RULE 5250(C)(1) (THE “RULE”), WHICH REQUIRES LISTED COMPANIES TO TIMELY FILE ALL PERIODIC FINANCIAL REPORTS WITH THE U.S. SECURITIES AND EXCHANGE COMMISSION (THE “SEC”).
|
EXICURE, INC. RECEIVED NASDAQ DELINQUENCY NOTICE ON LATE FILING OF ITS FORM 10-Q
|
XCUR
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-03-27 16:01:00
| null |
CHICAGO--(BUSINESS WIRE)--EXICURE, INC., REPORTED FINANCIAL RESULTS FOR THE YEAR ENDED DECEMBER 31, 2022 AND PROVIDED AN UPDATE ON ITS BUSINESS STRATEGY AND CORPORATE PROGRESS.
|
EXICURE, INC. REPORTS FULL YEAR 2022 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
|
XCUR
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-02-24 17:10:00
| null |
CHICAGO--(BUSINESS WIRE)--EXICURE TODAY ANNOUNCED THE CLOSING OF THE PREVIOUSLY-ANNOUNCED PRIVATE PLACEMENT TRANSACTION WITH CBI USA, INC. EFFECTIVE FEBRUARY 24, 2023.
|
EXICURE, INC. ANNOUNCES CLOSING OF PRIVATE PLACEMENT TRANSACTION WITH CBI USA, INC. AND CHANGES TO THE BOARD OF DIRECTORS
|
XCUR
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-12-14 05:00:00
| null |
CHICAGO--( BUSINESS WIRE )--EXICURE, INC. (NASDAQ: XCUR) AN EARLY-STAGE BIOTECHNOLOGY COMPANY HISTORICALLY FOCUSED ON DEVELOPING NUCLEIC ACID THERAPIES TARGETING RIBONUCLEIC ACID AGAINST VALIDATED TARGETS, TODAY ANNOUNCED THE TERMINATION OF ITS COLLABORATION AGREEMENTS WITH ABBVIE, INC. (ABBVIE) AND IPSEN BIOPHARM LIMITED (IPSEN).
|
EXICURE, INC. ANNOUNCES TERMINATION OF ABBVIE AND IPSEN COLLABORATION AGREEMENTS
|
XCUR
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-09-26 16:01:00
| null |
CHICAGO--(BUSINESS WIRE)--EXICURE ANNOUNCED PLANS TO RESTRUCTURE THE COMPANY AND ALIGN RESOURCES TO CONTINUE EXPLORING STRATEGIC ALTERNATIVES THAT MAXIMIZE STOCKHOLDER VALUE.
|
EXICURE, INC. ENTERS INTO DEFINITIVE AGREEMENT WITH CBI USA, INC. FOR $5.4 MILLION EQUITY FINANCING AND ANNOUNCES IMPLEMENTATION OF STRATEGIC MEASURE TO REDUCE CASH BURN AND PRIORITIZE STRATEGIC ALTERNATIVES
|
XCUR
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-09-01 07:00:00
| null |
CHICAGO--(BUSINESS WIRE)--EXICURE CEO MATTHIAS SCHROFF WILL PROVIDE A LIVE PRESENTATION AT THE 2022 CHARDAN GENETIC MEDICINES CONFERENCE.
|
EXICURE ANNOUNCES PRESENTATION AT CHARDAN'S 6TH ANNUAL GENETIC MEDICINES CONFERENCE
|
XCUR
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-06-29 12:00:00
| null |
CHICAGO--(BUSINESS WIRE)--EXICURE, INC. (NASDAQ: XCUR), AN EARLY-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON THE DEVELOPMENT OF NEXT GENERATION NUCLEIC ACID THERAPIES TARGETING RNA TO ADDRESS BOTH GENETIC AND NON-GENETIC NEUROLOGICAL DISORDERS AND HAIR LOSS DISORDERS, TODAY ANNOUNCED THAT, FOLLOWING THE IMPLEMENTATION OF A ONE-FOR-THIRTY REVERSE STOCK SPLIT AT 5:00 P.M. EDT TODAY, THE COMPANY'S COMMON STOCK WILL BEGIN TRADING ON A SPLIT-ADJUSTED BASIS ON NASDAQ EFFECTIVE WITH THE OPEN OF BUSINESS TO
|
EXICURE, INC. ANNOUNCES RECEIPT OF NASDAQ NOTICE OF NON-COMPLIANCE AND IMPLEMENTATION OF ONE-FOR-THIRTY REVERSE STOCK SPLIT
|
XCUR
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-05-27 16:01:00
| null |
CHICAGO--(BUSINESS WIRE)--EXICURE, INC. (NASDAQ: XCUR), AN EARLY-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON THE DEVELOPMENT OF NEXT GENERATION NUCLEIC ACID THERAPIES TARGETING RNA TO ADDRESS BOTH GENETIC AND NON-GENETIC NEUROLOGICAL DISORDERS AND HAIR LOSS DISORDERS, TODAY ANNOUNCED THAT THE COMPANY'S ANNUAL MEETING OF STOCKHOLDERS (THE “ANNUAL MEETING”) HELD IN VIRTUAL FORMAT ON FRIDAY, MAY 27, 2022 AT 1:00 P.M. CENTRAL TIME, WAS CONVENED AND ADJOURNED UNTIL JUNE 10, 2022 AT 1:00 P.M. CENTRAL TIME
|
EXICURE, INC. ANNOUNCES ADJOURNMENT OF ANNUAL MEETING OF STOCKHOLDERS
|
XCUR
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-05-17 07:00:00
| null |
CHICAGO--(BUSINESS WIRE)--EXICURE TODAY ANNOUNCED THAT CEO MATTHIAS SCHROFF WILL PROVIDE A VIRTUAL PRESENTATION AT THE 2022 H.C. WAINWRIGHT GLOBAL LIFE SCIENCES CONFERENCE.
|
EXICURE ANNOUNCES PRESENTATION AT 2022 H.C. WAINWRIGHT GLOBAL LIFE SCIENCES CONFERENCE
|
XCUR
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-05-10 19:21:00
| null |
CHICAGO--(BUSINESS WIRE)--EXICURE, INC.® (NASDAQ:XCUR), AN EARLY-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON THE DEVELOPMENT OF NEXT GENERATION NUCLEIC ACID THERAPIES TARGETING RNA TO ADDRESS BOTH GENETIC AND NON-GENETIC NEUROLOGICAL DISORDERS AND HAIR LOSS DISORDERS, TODAY ANNOUNCED THAT IT HAS AGREED TO SELL AN AGGREGATE OF 26,021,111 SHARES OF ITS COMMON STOCK AT A PURCHASE PRICE OF $0.1937 PER SHARE TO CERTAIN ACCREDITED INVESTORS IN A PRIVATE PLACEMENT IN PUBLIC EQUITY (“PIPE”) FINANCING. THE P
|
EXICURE ANNOUNCES $5 MILLION RAISE IN PRIVATE PLACEMENT TRANSACTION PRICED AT MARKET PREMIUM
|
XCUR
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-03-25 16:15:00
| null |
CHICAGO--(BUSINESS WIRE)--EXICURE, INC. (NASDAQ: XCUR), A PIONEER IN GENE REGULATORY AND IMMUNOTHERAPEUTIC DRUGS UTILIZING SPHERICAL NUCLEIC ACID (SNA™) TECHNOLOGY, TODAY REPORTED FULL YEAR FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED DECEMBER 31, 2021 AND PROVIDED AN UPDATE ON ITS BUSINESS STRATEGY AND CORPORATE PROGRESS. “THIS PAST YEAR BROUGHT SIGNIFICANT CHALLENGES TO OUR ORGANIZATION THAT PROMPTED STRATEGIC DECISIONS AT YEAR-END TO REFOCUS OUR BUSINESS STRATEGY ON OUR NEXT GENERATION P
|
EXICURE, INC. REPORTS FULL YEAR 2021 FINANCIAL RESULTS AND CORPORATE PROGRESS
|
XCUR
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-02-17 10:50:00
| null |
SAN DIEGO, CALIFORNIA--(NEWSFILE CORP. - FEBRUARY 17, 2022) - JOHNSON FISTEL, LLP IS INVESTIGATING POTENTIAL CLAIMS ON BEHALF OF EXICURE, INC. ("EXICURE" OR THE "COMPANY") (NASDAQ: XCUR) AGAINST CERTAIN OF ITS OFFICERS AND DIRECTORS.RECENTLY, A CLASS ACTION COMPLAINT WAS FILED AGAINST EXICURE. ACCORDING TO THE COMPLAINT, THROUGHOUT THE CLASS PERIOD, DEFENDANTS MADE MATERIALLY FALSE AND/OR MISLEADING STATEMENTS, AS WELL AS FAILED TO DISCLOSE MATERIAL ADVERSE FACTS ABOUT THE COMPANY'S BUSINESS, OPERATIONS, AND PROSPECTS. SPECIFICALLY,...
|
DID YOU ACQUIRE (XCUR) BEFORE JANUARY 7, 2021? SHOULD MANAGEMENT BE HELD ACCOUNTABLE FOR INVESTORS LOSSES?
|
XCUR
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-02-11 19:01:00
| null |
SECURITIES LITIGATION PARTNER JAMES (JOSH) WILSON ENCOURAGES INVESTORS WHO SUFFERED LOSSES EXCEEDING $100,000 IN EXICURE TO CONTACT HIM DIRECTLY TO DISCUSS THEIR OPTIONSNEW YORK, NEW YORK--(NEWSFILE CORP. - FEBRUARY 11, 2022) - FARUQI & FARUQI, LLP, A LEADING NATIONAL SECURITIES LAW FIRM, IS INVESTIGATING POTENTIAL CLAIMS AGAINST EXICURE, INC. ("EXICURE" OR THE "COMPANY") (NASDAQ: XCUR) AND REMINDS INVESTORS OF THE FEBRUARY 11, 2022 DEADLINE TO SEEK THE ROLE OF LEAD PLAINTIFF IN A FEDERAL SECURITIES CLASS ACTION THAT HAS BEEN FILED AGAINST THE COMPANY. IF YOU SUFFERED LOSSES EXCEEDING $100,000 INVESTING IN EXICURE STOCK OR OPTIONS...
|
EXICURE SHAREHOLDER ALERT
|
XCUR
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-02-10 16:26:00
| null |
NEW YORK, NEW YORK--(NEWSFILE CORP. - FEBRUARY 10, 2022) - POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF EXICURE, INC. ("EXICURE" OR THE "COMPANY") (NASDAQ: XCUR). SUCH INVESTORS ARE ADVISED TO CONTACT ROBERT S. WILLOUGHBY AT NEWACTION@POMLAW.COM OR 888-476-6529, EXT. 7980.THE INVESTIGATION CONCERNS WHETHER EXICURE AND CERTAIN OF ITS OFFICERS AND/OR DIRECTORS HAVE ENGAGED IN SECURITIES FRAUD OR OTHER UNLAWFUL BUSINESS PRACTICES. [CLICK HERE FOR INFORMATION ABOUT JOINING THE...
|
SHAREHOLDER ALERT: POMERANTZ LAW FIRM INVESTIGATES CLAIMS ON BEHALF OF INVESTORS OF EXICURE, INC. - XCUR
|
XCUR
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-02-10 15:00:00
| null |
LOS ANGELES--(BUSINESS WIRE)--THE LAW OFFICES OF FRANK R. CRUZ REMINDS INVESTORS OF THE UPCOMING FEBRUARY 11, 2022 DEADLINE TO FILE A LEAD PLAINTIFF MOTION IN THE CLASS ACTION FILED ON BEHALF OF INVESTORS WHO ACQUIRED EXICURE, INC. (“EXICURE” OR THE “COMPANY”) (NASDAQ: XCUR) SECURITIES BETWEEN JANUARY 7, 2021 AND DECEMBER 10, 2021, INCLUSIVE (THE “CLASS PERIOD”). IF YOU ARE A SHAREHOLDER WHO SUFFERED A LOSS, CLICK HERE TO PARTICIPATE. ON NOVEMBER 15, 2021, AFTER THE MARKET CLOSED, EXICURE FILED
|
THE LAW OFFICES OF FRANK R. CRUZ REMINDS INVESTORS OF LOOMING DEADLINE IN THE CLASS ACTION LAWSUIT AGAINST EXICURE, INC. (XCUR)
|
XCUR
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-02-10 13:16:00
| null |
LOS ANGELES, CALIFORNIA--(NEWSFILE CORP. - FEBRUARY 10, 2022) - THE SCHALL LAW FIRM, A NATIONAL SHAREHOLDER RIGHTS LITIGATION FIRM, REMINDS INVESTORS OF A CLASS ACTION LAWSUIT AGAINST EXICURE, INC. ("EXICURE" OR "THE COMPANY") (NASDAQ: XCUR) FOR VIOLATIONS OF §§10(B) AND 20(A) OF THE SECURITIES EXCHANGE ACT OF 1934 AND RULE 10B-5 PROMULGATED THEREUNDER BY THE U.S. SECURITIES AND EXCHANGE COMMISSION.
|
DEADLINE TOMORROW REMINDER: THE SCHALL LAW FIRM ENCOURAGES INVESTORS IN EXICURE, INC. WITH LOSSES OF $100,000 TO CONTACT THE FIRM
|
XCUR
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-02-10 11:00:00
| null |
NEW YORK, NEW YORK--(NEWSFILE CORP. - FEBRUARY 10, 2022) - WHY: ROSEN LAW FIRM, A GLOBAL INVESTOR RIGHTS LAW FIRM, REMINDS PURCHASERS OF THE SECURITIES OF EXICURE, INC. (NASDAQ: XCUR) BETWEEN MARCH 11, 2021 AND NOVEMBER 15, 2021, INCLUSIVE (THE "CLASS PERIOD") OF THE IMPORTANT FEBRUARY 11, 2022 LEAD PLAINTIFF DEADLINE.SO WHAT: IF YOU PURCHASED EXICURE SECURITIES DURING THE CLASS PERIOD YOU MAY BE ENTITLED TO COMPENSATION WITHOUT PAYMENT OF ANY OUT OF POCKET FEES...
|
XCUR FINAL DEADLINE: ROSEN, RESPECTED INVESTOR COUNSEL, ENCOURAGES EXICURE, INC. INVESTORS TO SECURE COUNSEL BEFORE IMPORTANT FRIDAY DEADLINE IN SECURITIES CLASS ACTION - XCUR
|
XCUR
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-02-09 13:12:00
| null |
LOS ANGELES, CALIFORNIA--(NEWSFILE CORP. - FEBRUARY 9, 2022) - THE SCHALL LAW FIRM, A NATIONAL SHAREHOLDER RIGHTS LITIGATION FIRM, REMINDS INVESTORS OF A CLASS ACTION LAWSUIT AGAINST EXICURE, INC. ("EXICURE" OR "THE COMPANY") (NASDAQ: XCUR) FOR VIOLATIONS OF §§10(B) AND 20(A) OF THE SECURITIES EXCHANGE ACT OF 1934 AND RULE 10B-5 PROMULGATED THEREUNDER BY THE U.S. SECURITIES AND EXCHANGE COMMISSION.
|
DEADLINE FRIDAY NOTICE: THE SCHALL LAW FIRM ENCOURAGES INVESTORS IN EXICURE, INC. WITH LOSSES OF $100,000 TO CONTACT THE FIRM
|
XCUR
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-02-08 12:08:00
| null |
LOS ANGELES, CALIFORNIA--(NEWSFILE CORP. - FEBRUARY 8, 2022) - THE SCHALL LAW FIRM, A NATIONAL SHAREHOLDER RIGHTS LITIGATION FIRM, REMINDS INVESTORS OF A CLASS ACTION LAWSUIT AGAINST EXICURE, INC. ("EXICURE" OR "THE COMPANY") (NASDAQ: XCUR) FOR VIOLATIONS OF §§10(B) AND 20(A) OF THE SECURITIES EXCHANGE ACT OF 1934 AND RULE 10B-5 PROMULGATED THEREUNDER BY THE U.S. SECURITIES AND EXCHANGE COMMISSION.
|
DEADLINE FRIDAY ALERT: THE SCHALL LAW FIRM ENCOURAGES INVESTORS IN EXICURE, INC. WITH LOSSES OF $100,000 TO CONTACT THE FIRM
|
XCUR
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-02-07 14:00:00
| null |
LOS ANGELES, FEB. 7, 2022 /PRNEWSWIRE/ -- THE LAW OFFICES OF FRANK R. CRUZ ANNOUNCES THAT A CLASS ACTION LAWSUIT HAS BEEN FILED ON BEHALF OF PERSONS AND ENTITIES THAT PURCHASED OR OTHERWISE ACQUIRED EXICURE, INC. ("EXICURE" OR THE "COMPANY") (NASDAQ: XCUR) SECURITIES BETWEEN MARCH 11, 2021 AND NOVEMBER 15, 2021 , INCLUSIVE (THE "CLASS PERIOD").
|
THE LAW OFFICES OF FRANK R. CRUZ ANNOUNCES THE FILING OF A SECURITIES CLASS ACTION ON BEHALF OF EXICURE, INC. (XCUR) INVESTORS
|
XCUR
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-02-07 12:05:00
| null |
LOS ANGELES, CALIFORNIA--(NEWSFILE CORP. - FEBRUARY 7, 2022) - THE SCHALL LAW FIRM, A NATIONAL SHAREHOLDER RIGHTS LITIGATION FIRM, REMINDS INVESTORS OF A CLASS ACTION LAWSUIT AGAINST EXICURE, INC. ("EXICURE" OR "THE COMPANY") (NASDAQ: XCUR) FOR VIOLATIONS OF §§10(B) AND 20(A) OF THE SECURITIES EXCHANGE ACT OF 1934 AND RULE 10B-5 PROMULGATED THEREUNDER BY THE U.S. SECURITIES AND EXCHANGE COMMISSION.
|
FRIDAY DEADLINE REMINDER: THE SCHALL LAW FIRM ENCOURAGES INVESTORS IN EXICURE, INC. WITH LOSSES OF $100,000 TO CONTACT THE FIRM
|
XCUR
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-02-06 08:32:00
| null |
SECURITIES LITIGATION PARTNER JAMES (JOSH) WILSON ENCOURAGES INVESTORS WHO SUFFERED LOSSES EXCEEDING $100,000 IN EXICURE TO CONTACT HIM DIRECTLY TO DISCUSS THEIR OPTIONSNEW YORK, NEW YORK--(NEWSFILE CORP. - FEBRUARY 6, 2022) - FARUQI & FARUQI, LLP, A LEADING NATIONAL SECURITIES LAW FIRM, IS INVESTIGATING POTENTIAL CLAIMS AGAINST EXICURE, INC. ("EXICURE" OR THE "COMPANY") (NASDAQ: XCUR) AND REMINDS INVESTORS OF THE FEBRUARY 11, 2022 DEADLINE TO SEEK THE ROLE OF LEAD PLAINTIFF IN A FEDERAL SECURITIES CLASS ACTION THAT HAS BEEN FILED AGAINST THE COMPANY. IF YOU SUFFERED LOSSES EXCEEDING $100,000 INVESTING IN EXICURE STOCK OR OPTIONS BETWEEN...
|
EXICURE CLASS ACTION REMINDER
|
XCUR
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-02-04 20:17:00
| null |
LOS ANGELES--(BUSINESS WIRE)--GLANCY PRONGAY & MURRAY LLP (“GPM”), ANNOUNCES THAT IT HAS FILED AN AMENDED CLASS ACTION COMPLAINT IN THE UNITED STATES DISTRICT COURT FOR THE NORTHERN DISTRICT OF ILLINOIS CAPTIONED COLWELL V. EXICURE, INC., ET AL., (CASE NO. 21-CV-6637), EXPANDING THE CLASS DEFINITION TO ENCOMPASS PERSONS AND ENTITIES THAT PURCHASED OR OTHERWISE ACQUIRED EXICURE, INC. (“EXICURE” OR THE “COMPANY”) (NASDAQ: XCUR) SECURITIES BETWEEN JANUARY 7, 2021 AND DECEMBER 10, 2021, INCLUSI
|
GLANCY PRONGAY & MURRAY LLP EXPANDS CLASS PERIOD IN THE SECURITIES FRAUD LAWSUIT AGAINST EXICURE, INC. (XCUR)
|
XCUR
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-02-04 19:43:00
| null |
NEW YORK, FEB. 4, 2022 /PRNEWSWIRE/ -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF EXICURE, INC. ("EXICURE" OR THE "COMPANY") (NASDAQ: XCUR). SUCH INVESTORS ARE ADVISED TO CONTACT ROBERT S.
|
SHAREHOLDER ALERT: POMERANTZ LAW FIRM INVESTIGATES CLAIMS ON BEHALF OF INVESTORS OF EXICURE, INC. - XCUR
|
XCUR
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-02-04 07:00:00
| null |
CHICAGO--(BUSINESS WIRE)--EXICURE, INC. ANNOUNCES LEADERSHIP TRANSITION AND CHANGES TO THE BOARD OF DIRECTORS
|
EXICURE, INC. ANNOUNCES LEADERSHIP TRANSITION AND CHANGES TO THE BOARD OF DIRECTORS
|
XCUR
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-02-03 17:51:00
| null |
NEW YORK, FEB. 3, 2022 /PRNEWSWIRE/ -- WHY: ROSEN LAW FIRM, A GLOBAL INVESTOR RIGHTS LAW FIRM, REMINDS PURCHASERS OF THE SECURITIES OF EXICURE, INC. (NASDAQ: XCUR) BETWEEN MARCH 11, 2021 AND NOVEMBER 15, 2021, INCLUSIVE (THE "CLASS PERIOD") OF THE IMPORTANT FEBRUARY 11, 2022 LEAD PLAINTIFF DEADLINE. SO WHAT: IF YOU PURCHASED EXICURE SECURITIES DURING THE CLASS PERIOD YOU MAY BE ENTITLED TO COMPENSATION WITHOUT PAYMENT OF ANY OUT OF POCKET FEES OR COSTS THROUGH A CONTINGENCY FEE ARRANGEMENT.
|
ROSEN, A RESPECTED AND LEADING FIRM, ENCOURAGES EXICURE, INC. INVESTORS WITH LOSSES OVER $100K TO SECURE COUNSEL BEFORE IMPORTANT FEBRUARY 11 DEADLINE IN SECURITIES CLASS ACTION - XCUR
|
XCUR
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-02-02 19:50:00
| null |
NEW YORK, NEW YORK--(NEWSFILE CORP. - FEBRUARY 2, 2022) - POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF EXICURE, INC. ("EXICURE" OR THE "COMPANY") (NASDAQ: XCUR). SUCH INVESTORS ARE ADVISED TO CONTACT ROBERT S. WILLOUGHBY AT NEWACTION@POMLAW.COM OR 888-476-6529, EXT. 7980.THE INVESTIGATION CONCERNS WHETHER EXICURE AND CERTAIN OF ITS OFFICERS AND/OR DIRECTORS HAVE ENGAGED IN SECURITIES FRAUD OR OTHER UNLAWFUL BUSINESS PRACTICES. [CLICK HERE FOR INFORMATION ABOUT JOINING THE...
|
SHAREHOLDER ALERT: POMERANTZ LAW FIRM INVESTIGATES CLAIMS ON BEHALF OF INVESTORS OF EXICURE, INC. - XCUR
|
XCUR
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-02-01 18:44:00
| null |
SECURITIES LITIGATION PARTNER JAMES (JOSH) WILSON ENCOURAGES INVESTORS WHO SUFFERED LOSSES EXCEEDING $100,000 IN EXICURE TO CONTACT HIM DIRECTLY TO DISCUSS THEIR OPTIONSNEW YORK, NEW YORK--(NEWSFILE CORP. - FEBRUARY 1, 2022) - FARUQI & FARUQI, LLP, A LEADING NATIONAL SECURITIES LAW FIRM, IS INVESTIGATING POTENTIAL CLAIMS AGAINST EXICURE, INC. ("EXICURE" OR THE "COMPANY") (NASDAQ: XCUR) AND REMINDS INVESTORS OF THE FEBRUARY 11, 2022 DEADLINE TO SEEK THE ROLE OF LEAD PLAINTIFF IN A FEDERAL SECURITIES CLASS ACTION THAT HAS BEEN FILED AGAINST THE COMPANY. IF YOU SUFFERED LOSSES EXCEEDING $100,000 INVESTING IN EXICURE STOCK OR OPTIONS BETWEEN...
|
EXICURE SHAREHOLDER ALERT
|
XCUR
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-02-01 15:06:00
| null |
NEW YORK, NEW YORK--(NEWSFILE CORP. - FEBRUARY 1, 2022) - WHY: ROSEN LAW FIRM, A GLOBAL INVESTOR RIGHTS LAW FIRM, REMINDS PURCHASERS OF THE SECURITIES OF EXICURE, INC. (NASDAQ: XCUR) BETWEEN MARCH 11, 2021 AND NOVEMBER 15, 2021, INCLUSIVE (THE "CLASS PERIOD") OF THE IMPORTANT FEBRUARY 11, 2022 LEAD PLAINTIFF DEADLINE.SO WHAT: IF YOU PURCHASED EXICURE SECURITIES DURING THE CLASS PERIOD YOU MAY BE ENTITLED TO COMPENSATION WITHOUT PAYMENT OF ANY OUT OF POCKET...
|
XCUR LOSS ALERT: ROSEN, LEADING INVESTOR COUNSEL, ENCOURAGES EXICURE, INC. INVESTORS WITH LOSSES TO SECURE COUNSEL BEFORE IMPORTANT FEBRUARY 11 DEADLINE IN SECURITIES CLASS ACTION - XCUR
|
XCUR
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-02-01 12:10:00
| null |
LOS ANGELES, CALIFORNIA--(NEWSFILE CORP. - FEBRUARY 1, 2022) - THE SCHALL LAW FIRM, A NATIONAL SHAREHOLDER RIGHTS LITIGATION FIRM, REMINDS INVESTORS OF A CLASS ACTION LAWSUIT AGAINST EXICURE, INC. ("EXICURE" OR "THE COMPANY") (NASDAQ: XCUR) FOR VIOLATIONS OF §§10(B) AND 20(A) OF THE SECURITIES EXCHANGE ACT OF 1934 AND RULE 10B-5 PROMULGATED THEREUNDER BY THE U.S. SECURITIES AND EXCHANGE COMMISSION.
|
SHAREHOLDER ACTION NOTICE: THE SCHALL LAW FIRM ENCOURAGES INVESTORS IN EXICURE, INC. WITH LOSSES OF $100,000 TO CONTACT THE FIRM
|
XCUR
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-01-31 12:05:00
| null |
LOS ANGELES, CALIFORNIA--(NEWSFILE CORP. - JANUARY 31, 2022) - THE SCHALL LAW FIRM, A NATIONAL SHAREHOLDER RIGHTS LITIGATION FIRM, REMINDS INVESTORS OF A CLASS ACTION LAWSUIT AGAINST EXICURE, INC. ("EXICURE" OR "THE COMPANY") (NASDAQ: XCUR) FOR VIOLATIONS OF §§10(B) AND 20(A) OF THE SECURITIES EXCHANGE ACT OF 1934 AND RULE 10B-5 PROMULGATED THEREUNDER BY THE U.S. SECURITIES AND EXCHANGE COMMISSION.
|
SHAREHOLDER ACTION ALERT: THE SCHALL LAW FIRM ENCOURAGES INVESTORS IN EXICURE, INC. WITH LOSSES OF $100,000 TO CONTACT THE FIRM
|
XCUR
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-01-28 18:13:00
| null |
SECURITIES LITIGATION PARTNER JAMES (JOSH) WILSON ENCOURAGES INVESTORS WHO SUFFERED LOSSES EXCEEDING $100,000 IN EXICURE TO CONTACT HIM DIRECTLY TO DISCUSS THEIR OPTIONSNEW YORK, NEW YORK--(NEWSFILE CORP. - JANUARY 28, 2022) - FARUQI & FARUQI, LLP, A LEADING NATIONAL SECURITIES LAW FIRM, IS INVESTIGATING POTENTIAL CLAIMS AGAINST EXICURE, INC. ("EXICURE" OR THE "COMPANY") (NASDAQ: XCUR) AND REMINDS INVESTORS OF THE FEBRUARY 11, 2022 DEADLINE TO SEEK THE ROLE OF LEAD PLAINTIFF IN A FEDERAL SECURITIES CLASS ACTION THAT HAS BEEN FILED AGAINST THE COMPANY. IF YOU SUFFERED LOSSES EXCEEDING $100,000 INVESTING IN EXICURE STOCK OR OPTIONS BETWEEN...
|
EXICURE SHAREHOLDER ALERT
|
XCUR
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-01-28 14:43:00
| null |
LOS ANGELES, CALIFORNIA--(NEWSFILE CORP. - JANUARY 28, 2022) - THE SCHALL LAW FIRM, A NATIONAL SHAREHOLDER RIGHTS LITIGATION FIRM, REMINDS INVESTORS OF A CLASS ACTION LAWSUIT AGAINST EXICURE, INC. ("EXICURE" OR "THE COMPANY") (NASDAQ: XCUR) FOR VIOLATIONS OF §§10(B) AND 20(A) OF THE SECURITIES EXCHANGE ACT OF 1934 AND RULE 10B-5 PROMULGATED THEREUNDER BY THE U.S. SECURITIES AND EXCHANGE COMMISSION.
|
INVESTOR ACTION REMINDER: THE SCHALL LAW FIRM ENCOURAGES INVESTORS IN EXICURE, INC. WITH LOSSES OF $100,000 TO CONTACT THE FIRM
|
XCUR
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-01-28 13:00:00
| null |
BENSALEM, PA., JAN. 28, 2022 /PRNEWSWIRE/ -- LAW OFFICES OF HOWARD G.
|
XCUR INVESTORS HAVE OPPORTUNITY TO LEAD EXICURE, INC. SECURITIES FRAUD LAWSUIT
|
XCUR
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-01-27 18:25:00
| null |
NEW YORK, JAN. 27, 2022 /PRNEWSWIRE/ -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF EXICURE, INC. ("EXICURE" OR THE "COMPANY") (NASDAQ: XCUR). SUCH INVESTORS ARE ADVISED TO CONTACT ROBERT S.
|
SHAREHOLDER ALERT: POMERANTZ LAW FIRM INVESTIGATES CLAIMS ON BEHALF OF INVESTORS OF EXICURE, INC. - XCUR
|
XCUR
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-01-26 12:52:00
| null |
LOS ANGELES, CALIFORNIA--(NEWSFILE CORP. - JANUARY 26, 2022) - THE SCHALL LAW FIRM, A NATIONAL SHAREHOLDER RIGHTS LITIGATION FIRM, REMINDS INVESTORS OF A CLASS ACTION LAWSUIT AGAINST EXICURE, INC. ("EXICURE" OR "THE COMPANY") (NASDAQ: XCUR) FOR VIOLATIONS OF §§10(B) AND 20(A) OF THE SECURITIES EXCHANGE ACT OF 1934 AND RULE 10B-5 PROMULGATED THEREUNDER BY THE U.S. SECURITIES AND EXCHANGE COMMISSION.
|
SHAREHOLDER ACTION ALERT: THE SCHALL LAW FIRM ENCOURAGES INVESTORS IN EXICURE, INC. WITH LOSSES OF $100,000 TO CONTACT THE FIRM
|
XCUR
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-01-25 21:19:00
| null |
NEW YORK, JAN. 25, 2022 /PRNEWSWIRE/ -- WHY: ROSEN LAW FIRM, A GLOBAL INVESTOR RIGHTS LAW FIRM, REMINDS PURCHASERS OF THE SECURITIES OF EXICURE, INC. (NASDAQ: XCUR) BETWEEN MARCH 11, 2021 AND NOVEMBER 15, 2021, INCLUSIVE (THE "CLASS PERIOD") OF THE IMPORTANT FEBRUARY 11, 2022 LEAD PLAINTIFF DEADLINE. SO WHAT: IF YOU PURCHASED EXICURE SECURITIES DURING THE CLASS PERIOD YOU MAY BE ENTITLED TO COMPENSATION WITHOUT PAYMENT OF ANY OUT OF POCKET FEES OR COSTS THROUGH A CONTINGENCY FEE ARRANGEMENT.
|
ROSEN, GLOBAL INVESTOR COUNSEL, ENCOURAGES EXICURE, INC. INVESTORS WITH LOSSES OVER $100K TO SECURE COUNSEL BEFORE IMPORTANT FEBRUARY 11 DEADLINE IN SECURITIES CLASS ACTION - XCUR
|
XCUR
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-01-25 12:47:00
| null |
LOS ANGELES, CALIFORNIA--(NEWSFILE CORP. - JANUARY 25, 2022) - THE SCHALL LAW FIRM, A NATIONAL SHAREHOLDER RIGHTS LITIGATION FIRM, REMINDS INVESTORS OF A CLASS ACTION LAWSUIT AGAINST EXICURE, INC. ("EXICURE" OR "THE COMPANY") (NASDAQ: XCUR) FOR VIOLATIONS OF §§10(B) AND 20(A) OF THE SECURITIES EXCHANGE ACT OF 1934 AND RULE 10B-5 PROMULGATED THEREUNDER BY THE U.S. SECURITIES AND EXCHANGE COMMISSION.
|
INVESTOR ACTION REMINDER: THE SCHALL LAW FIRM ENCOURAGES INVESTORS IN EXICURE, INC. WITH LOSSES OF $100,000 TO CONTACT THE FIRM
|
XCUR
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-01-24 12:44:00
| null |
LOS ANGELES, CALIFORNIA--(NEWSFILE CORP. - JANUARY 24, 2022) - THE SCHALL LAW FIRM, A NATIONAL SHAREHOLDER RIGHTS LITIGATION FIRM, REMINDS INVESTORS OF A CLASS ACTION LAWSUIT AGAINST EXICURE, INC. ("EXICURE" OR "THE COMPANY") (NASDAQ: XCUR) FOR VIOLATIONS OF §§10(B) AND 20(A) OF THE SECURITIES EXCHANGE ACT OF 1934 AND RULE 10B-5 PROMULGATED THEREUNDER BY THE U.S. SECURITIES AND EXCHANGE COMMISSION.
|
SHAREHOLDER ACTION NOTICE: THE SCHALL LAW FIRM ENCOURAGES INVESTORS IN EXICURE, INC. WITH LOSSES OF $100,000 TO CONTACT THE FIRM
|
XCUR
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-01-23 10:10:00
| null |
NEW YORK, NEW YORK--(NEWSFILE CORP. - JANUARY 23, 2022) - WHY: ROSEN LAW FIRM, A GLOBAL INVESTOR RIGHTS LAW FIRM, REMINDS PURCHASERS OF THE SECURITIES OF EXICURE, INC. (NASDAQ: XCUR) BETWEEN MARCH 11, 2021 AND NOVEMBER 15, 2021, INCLUSIVE (THE "CLASS PERIOD") OF THE IMPORTANT FEBRUARY 11, 2022 LEAD PLAINTIFF DEADLINE.SO WHAT: IF YOU PURCHASED EXICURE SECURITIES DURING THE CLASS PERIOD YOU MAY BE ENTITLED TO COMPENSATION WITHOUT PAYMENT OF ANY OUT OF POCKET FEES OR...
|
ROSEN, A TOP RANKED LAW FIRM, ENCOURAGES EXICURE, INC. INVESTORS WITH LOSSES OVER $100K TO SECURE COUNSEL BEFORE IMPORTANT FEBRUARY 11 DEADLINE IN SECURITIES CLASS ACTION - XCUR
|
XCUR
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-01-21 18:20:00
| null |
SECURITIES LITIGATION PARTNER JAMES (JOSH) WILSON ENCOURAGES INVESTORS WHO SUFFERED LOSSES EXCEEDING $100,000 IN EXICURE TO CONTACT HIM DIRECTLY TO DISCUSS THEIR OPTIONSNEW YORK, NEW YORK--(NEWSFILE CORP. - JANUARY 21, 2022) - FARUQI & FARUQI, LLP, A LEADING NATIONAL SECURITIES LAW FIRM, IS INVESTIGATING POTENTIAL CLAIMS AGAINST EXICURE, INC. ("EXICURE" OR THE "COMPANY") (NASDAQ: XCUR) AND REMINDS INVESTORS OF THE FEBRUARY 11, 2022 DEADLINE TO SEEK THE ROLE OF LEAD PLAINTIFF IN A FEDERAL SECURITIES CLASS ACTION THAT HAS BEEN FILED AGAINST THE COMPANY. IF YOU SUFFERED LOSSES EXCEEDING $100,000 INVESTING IN EXICURE STOCK OR OPTIONS BETWEEN...
|
EXICURE SHAREHOLDER ALERT
|
XCUR
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-01-21 16:38:00
| null |
LOS ANGELES, CALIFORNIA--(NEWSFILE CORP. - JANUARY 21, 2022) - THE SCHALL LAW FIRM, A NATIONAL SHAREHOLDER RIGHTS LITIGATION FIRM, REMINDS INVESTORS OF A CLASS ACTION LAWSUIT AGAINST EXICURE, INC. ("EXICURE" OR "THE COMPANY") (NASDAQ: XCUR) FOR VIOLATIONS OF §§10(B) AND 20(A) OF THE SECURITIES EXCHANGE ACT OF 1934 AND RULE 10B-5 PROMULGATED THEREUNDER BY THE U.S. SECURITIES AND EXCHANGE COMMISSION.
|
SHAREHOLDER ACTION ALERT: THE SCHALL LAW FIRM ENCOURAGES INVESTORS IN EXICURE, INC. WITH LOSSES OF $100,000 TO CONTACT THE FIRM
|
XCUR
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-01-20 16:35:00
| null |
LOS ANGELES, CALIFORNIA--(NEWSFILE CORP. - JANUARY 20, 2022) - THE SCHALL LAW FIRM, A NATIONAL SHAREHOLDER RIGHTS LITIGATION FIRM, REMINDS INVESTORS OF A CLASS ACTION LAWSUIT AGAINST EXICURE, INC. ("EXICURE" OR "THE COMPANY") (NASDAQ: XCUR) FOR VIOLATIONS OF §§10(B) AND 20(A) OF THE SECURITIES EXCHANGE ACT OF 1934 AND RULE 10B-5 PROMULGATED THEREUNDER BY THE U.S. SECURITIES AND EXCHANGE COMMISSION.
|
INVESTOR ACTION REMINDER: THE SCHALL LAW FIRM ENCOURAGES INVESTORS IN EXICURE, INC. WITH LOSSES OF $100,000 TO CONTACT THE FIRM
|
XCUR
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-01-20 13:00:00
| null |
LOS ANGELES , JAN. 20, 2022 /PRNEWSWIRE/ -- GLANCY PRONGAY & MURRAY LLP ("GPM") ANNOUNCES THAT INVESTORS WITH SUBSTANTIAL LOSSES HAVE OPPORTUNITY TO LEAD THE SECURITIES FRAUD CLASS ACTION LAWSUIT AGAINST EXICURE, INC. ("EXICURE" OR THE "COMPANY") (NASDAQ: XCUR). CLASS PERIOD: MARCH 11, 2021 – NOVEMBER 15, 2021 LEAD PLAINTIFF DEADLINE: FEBRUARY 11, 2022 IF YOU WISH TO SERVE AS LEAD PLAINTIFF OF THE EXICURE LAWSUIT, YOU CAN SUBMIT YOUR CONTACT INFORMATION AT WWW.GLANCYLAW.COM/CASES/EXICURE-INC/.
|
XCUR INVESTORS HAVE OPPORTUNITY TO LEAD EXICURE, INC. SECURITIES FRAUD LAWSUIT
|
XCUR
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-01-19 21:24:00
| null |
NEW YORK, NEW YORK--(NEWSFILE CORP. - JANUARY 19, 2022) - POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF EXICURE, INC. ("EXICURE" OR THE "COMPANY") (NASDAQ: XCUR). SUCH INVESTORS ARE ADVISED TO CONTACT ROBERT S. WILLOUGHBY AT NEWACTION@POMLAW.COM OR 888-476-6529, EXT. 7980.THE INVESTIGATION CONCERNS WHETHER EXICURE AND CERTAIN OF ITS OFFICERS AND/OR DIRECTORS HAVE ENGAGED IN SECURITIES FRAUD OR OTHER UNLAWFUL BUSINESS PRACTICES. [CLICK HERE FOR INFORMATION ABOUT JOINING THE...
|
SHAREHOLDER ALERT: POMERANTZ LAW FIRM INVESTIGATES CLAIMS ON BEHALF OF INVESTORS OF EXICURE, INC. - XCUR
|
XCUR
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-01-19 16:33:00
| null |
LOS ANGELES, CALIFORNIA--(NEWSFILE CORP. - JANUARY 19, 2022) - THE SCHALL LAW FIRM, A NATIONAL SHAREHOLDER RIGHTS LITIGATION FIRM, REMINDS INVESTORS OF A CLASS ACTION LAWSUIT AGAINST EXICURE, INC. ("EXICURE" OR "THE COMPANY") (NASDAQ: XCUR) FOR VIOLATIONS OF §§10(B) AND 20(A) OF THE SECURITIES EXCHANGE ACT OF 1934 AND RULE 10B-5 PROMULGATED THEREUNDER BY THE U.S. SECURITIES AND EXCHANGE COMMISSION.
|
SHAREHOLDER ACTION NOTICE: THE SCHALL LAW FIRM ENCOURAGES INVESTORS IN EXICURE, INC. WITH LOSSES OF $100,000 TO CONTACT THE FIRM
|
XCUR
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-01-18 16:30:00
| null |
LOS ANGELES, CALIFORNIA--(NEWSFILE CORP. - JANUARY 18, 2022) - THE SCHALL LAW FIRM, A NATIONAL SHAREHOLDER RIGHTS LITIGATION FIRM, REMINDS INVESTORS OF A CLASS ACTION LAWSUIT AGAINST EXICURE, INC. ("EXICURE" OR "THE COMPANY") (NASDAQ: XCUR) FOR VIOLATIONS OF §§10(B) AND 20(A) OF THE SECURITIES EXCHANGE ACT OF 1934 AND RULE 10B-5 PROMULGATED THEREUNDER BY THE U.S. SECURITIES AND EXCHANGE COMMISSION.
|
SHAREHOLDER ACTION ALERT: THE SCHALL LAW FIRM ENCOURAGES INVESTORS IN EXICURE, INC. WITH LOSSES OF $100,000 TO CONTACT THE FIRM
|
XCUR
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-01-17 21:14:00
| null |
NEW YORK , JAN. 17, 2022 /PRNEWSWIRE/ -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF EXICURE, INC. ("EXICURE" OR THE "COMPANY") (NASDAQ: XCUR). SUCH INVESTORS ARE ADVISED TO CONTACT ROBERT S.
|
SHAREHOLDER ALERT: POMERANTZ LAW FIRM INVESTIGATES CLAIMS ON BEHALF OF INVESTORS OF EXICURE, INC. - XCUR
|
XCUR
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-01-17 19:31:00
| null |
SECURITIES LITIGATION PARTNER JAMES (JOSH) WILSON ENCOURAGES INVESTORS WHO SUFFERED LOSSES EXCEEDING $100,000 IN EXICURE TO CONTACT HIM DIRECTLY TO DISCUSS THEIR OPTIONSNEW YORK, NEW YORK--(NEWSFILE CORP. - JANUARY 17, 2022) - FARUQI & FARUQI, LLP, A LEADING NATIONAL SECURITIES LAW FIRM, IS INVESTIGATING POTENTIAL CLAIMS AGAINST EXICURE, INC. ("EXICURE" OR THE "COMPANY") (NASDAQ: XCUR) AND REMINDS INVESTORS OF THE FEBRUARY 11, 2022 DEADLINE TO SEEK THE ROLE OF LEAD PLAINTIFF IN A FEDERAL SECURITIES CLASS ACTION THAT HAS BEEN FILED AGAINST THE COMPANY. IF YOU SUFFERED LOSSES EXCEEDING $100,000 INVESTING IN EXICURE STOCK OR OPTIONS BETWEEN...
|
EXICURE SHAREHOLDER ALERT
|
XCUR
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.